The leukapheresis market was estimated to be worth USD 90.6 million in 2026 and is poised to reach USD 138.7 million by 2031, growing at a CAGR of 8.9%. The leukopaks market was estimated to be worth USD 432.1 million in 2026 and is poised to reach USD 1.88 billion by 2031, growing at a CAGR of 34.2%. ![Leukapheresis Market]( "Leukapheresis Market")
On top of that, the increasing incidence of hematologic disorders, autoimmune diseases, and immune-mediated conditions is driving up the demand for high-quality leukocyte collections. Hospitals and research centers are leaning toward advanced leukapheresis modalities, such as continuous, flow apheresis systems, membrane-based separators, and automated GMP-compliant platforms, as they are more precise, efficient, and scalable for cell collection.
Also, the market expansion is being spurred by the transition toward digital apheresis workflows, which include electronic documentation, donor-monitoring systems, and integrated data platforms. This shift not only helps in procedure standardization but also enables remote monitoring and connectivity with cell therapy manufacturing records. Besides that, technological advances, including AI, assisted cell, quality assessment, predictive analytics, and cloud-based workflow management, are playing a part in the market growth. They increase the efficiency of collection, traceability, and usability, thus providing advanced leukapheresis solutions with increased practicality in diverse clinical and research settings, ranging from large hospitals to standalone apheresis centers.
This growth is driven by several key factors shaping the future of leukapheresis procedures, clinical decision-making, and advanced cell-collection workflows.
The rising number of hematologic disorders and the increasing need for high-quality leukocyte collections to facilitate cell and gene therapy development and therapeutic interventions are the main factors that continue to drive growth. With the increasing use of CAR-T, TCR, NK cell therapies, and other immunotherapies, hospitals, blood centers, and apheresis units are rapidly upgrading their leukapheresis capabilities by acquiring advanced leukapheresis systems that feature automated controls, continuous, flow platforms, and GMP, compliant disposables, which help them to improve collection accuracy, maintain cell viability, and achieve timely clinical interventions.On top of that, the increasing incidence of hematologic disorders, autoimmune diseases, and immune-mediated conditions is driving up the demand for high-quality leukocyte collections. Hospitals and research centers are leaning toward advanced leukapheresis modalities, such as continuous, flow apheresis systems, membrane-based separators, and automated GMP-compliant platforms, as they are more precise, efficient, and scalable for cell collection.
Also, the market expansion is being spurred by the transition toward digital apheresis workflows, which include electronic documentation, donor-monitoring systems, and integrated data platforms. This shift not only helps in procedure standardization but also enables remote monitoring and connectivity with cell therapy manufacturing records. Besides that, technological advances, including AI, assisted cell, quality assessment, predictive analytics, and cloud-based workflow management, are playing a part in the market growth. They increase the efficiency of collection, traceability, and usability, thus providing advanced leukapheresis solutions with increased practicality in diverse clinical and research settings, ranging from large hospitals to standalone apheresis centers.
The disposables segment is projected to record the fastest growth by type during the forecast period.
Globally, the disposables segment dominated the leukapheresis market in 2025, primarily due to the increasing emphasis on standardized workflows, strict sterilization practices, and robust traceability requirements in healthcare systems. These factors collectively amplified the demand for single-use consumables. Disposables are essential in cell and gene therapy-related collections, where maintaining process uniformity, preventing contamination, and ensuring accurate documentation are critical. With the rapid global expansion of CGT manufacturing, including CAR-T, TCR-T, and stem-cell programs, the need for single-use kits, tubing sets, collection bags, filters, and closed-system consumables continues to rise steadily.The academic & research institutes segment accounted for the largest share of the leukopaks market.
By end user, the leukopaks market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, and contract research organizations. In 2025, the academic & research institutes segment accounted for the largest share of the leukapheresis products market. The increasing number of industry-academic partnerships for conducting research on cell-based cancer therapies is driving the growth of this end-user segment.Asia Pacific is projected to witness the highest growth during the forecast period.
During the forecast period, the Asia Pacific region is expected to record the highest growth rate in the leukapheresis market. Some of the major reasons that work toward the growth of the market are the rising cases of hematologic disorders, the increasing use of cell and gene therapy, the development of apheresis infrastructure, and the growing investment in advanced therapeutic technologies by regional as well as global players. Moreover, the region benefits from increased public awareness of novel treatment modalities, healthcare access enhancement, rapid growth of specialty hospitals and blood transfusion centers, and higher involvement in CGT-related clinical trials. Altogether, these elements will stimulate the demand for leukapheresis procedures and consumables in Asia Pacific countries.Breakdown of supply-side primary interviews:
- By Company Type: Tier 1 (45%), Tier 2 (20%), and Tier 3 (35%)
- By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
- By Region: North America (40%), Europe (25%), Asia Pacific (20%), Latin America (10%), and the Middle East & Africa (5%)
Breakdown of demand-side primary interviews:
- By End User: Academic & Research Institutes (45%), Pharmaceutical & Biotechnology Companies (30%), Contract Research Organizations (25%)
- By Designation: Apheresis Nurses & Practitioners (47%), Hematologists/Oncologists(22%), GMP Facility Heads (15%), and Others (16%)
- By Region: North America (25%), Europe (24%), Asia Pacific (25%), Latin America (11%), and the Middle East & Africa (15%)
Research Coverage
The market study covers the leukapheresis market in various segments. It aims to estimate the market size and growth potential of this market by type, application, end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their products and business offerings, recent developments, and key market strategies.Reasons to Buy the Report
The report can assist established companies and newer or smaller firms in understanding market trends, enabling them to capture a larger market share. Firms that acquire the report can implement one or more of the five strategies outlined below.This report provides insights into the following points:
- Analysis of key drivers, restraints, opportunities, and challenges
- Product Development/Innovation: Detailed insights on upcoming technologies and product launches in the leukapheresis market
- Market Development: Comprehensive information about lucrative emerging markets
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the leukapheresis market
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the leukapheresis market
Table of Contents
1 Introduction
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Market Segmentation & Regional Scope
1.3.2 Inclusions and Exclusions of Study
1.3.3 Years Considered
1.4 Currency Considered
1.5 Stakeholders
1.6 Summary of Changes
1.2 Market Definition
1.3 Study Scope
1.3.1 Market Segmentation & Regional Scope
1.3.2 Inclusions and Exclusions of Study
1.3.3 Years Considered
1.4 Currency Considered
1.5 Stakeholders
1.6 Summary of Changes
2 Executive Summary
2.1 Market Highlights and Key Insights
2.2 Leukopaks Market Participants: Mapping of Strategic Developments
2.3 Leukapheresis Market Participants: Mapping of Strategic Developments
2.4 Disruptive Trends in Leukapheresis Market
2.5 High-Growth Segments
2.6 Regional Snapshot: Market Size, Growth Rate, and Forecast
2.2 Leukopaks Market Participants: Mapping of Strategic Developments
2.3 Leukapheresis Market Participants: Mapping of Strategic Developments
2.4 Disruptive Trends in Leukapheresis Market
2.5 High-Growth Segments
2.6 Regional Snapshot: Market Size, Growth Rate, and Forecast
3 Premium Insights
3.1 Attractive Opportunities for Players in Leukapheresis Market
3.2 Asia-Pacific: Leukapheresis Market, by End User and Country
3.3 Geographic Snapshot of Leukaphersis Market
3.4 Attractive Opportunities for Players in Leukopaks Market
3.5 Asia-Pacific: Leukopaks Market, by Type and Country
3.6 Geographic Snapshot of Leukopaks Market
3.2 Asia-Pacific: Leukapheresis Market, by End User and Country
3.3 Geographic Snapshot of Leukaphersis Market
3.4 Attractive Opportunities for Players in Leukopaks Market
3.5 Asia-Pacific: Leukopaks Market, by Type and Country
3.6 Geographic Snapshot of Leukopaks Market
4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Rising Utilization of Leukopaks in Car-T Cell Therapy Development
4.2.1.2 Increasing Incidence and Clinical Burden of Leukemia
4.2.1.3 Leukopaks and Leukapheresis Driving Advances in Research & Development Activities
4.2.1.4 Leukopaks as Key Contributors to Car-T Cell Therapy Clinical Trials
4.2.2 Restraints
4.2.2.1 Elevated Costs of Therapeutic Leukapheresis and Leukopak Products
4.2.2.2 Limited Donor Availability and Stringent Screening Criteria for Leukapheresis
4.2.2.3 Shortage of Skilled Healthcare Professionals in Apheresis and Cell Therapy Procedures
4.2.2.4 Complications Associated With Therapeutic Leukapheresis
4.2.3 Opportunities
4.2.3.1 Increasing Focus on Leukapheresis in Pediatric Patients
4.2.3.2 Rise in Investments in Car-T Therapies in Emerging Economies
4.2.3.3 Gaps in Current Leukapheresis Technologies
4.2.4 Challenges
4.2.4.1 Infectious Disease Risks Related to Safety of Blood Transfusion in Emerging Economies
4.2.4.2 Donor Variability and Inconsistent Leukopak Quality
4.3 Unmet Needs & White Spaces
4.3.1 Unmet Needs in Leukapheresis Market
4.3.2 White Space Opportunities
4.4 Interconnected Markets & Cross-Sector Opportunities
4.4.1 Interconnected Markets
4.4.2 Cross-Sector Opportunities
4.5 Strategic Moves by Tier-1/2/3 Players
4.5.1 Strategic Moves by Tier 1/2/3 Players in Leukapheresis Market
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Rising Utilization of Leukopaks in Car-T Cell Therapy Development
4.2.1.2 Increasing Incidence and Clinical Burden of Leukemia
4.2.1.3 Leukopaks and Leukapheresis Driving Advances in Research & Development Activities
4.2.1.4 Leukopaks as Key Contributors to Car-T Cell Therapy Clinical Trials
4.2.2 Restraints
4.2.2.1 Elevated Costs of Therapeutic Leukapheresis and Leukopak Products
4.2.2.2 Limited Donor Availability and Stringent Screening Criteria for Leukapheresis
4.2.2.3 Shortage of Skilled Healthcare Professionals in Apheresis and Cell Therapy Procedures
4.2.2.4 Complications Associated With Therapeutic Leukapheresis
4.2.3 Opportunities
4.2.3.1 Increasing Focus on Leukapheresis in Pediatric Patients
4.2.3.2 Rise in Investments in Car-T Therapies in Emerging Economies
4.2.3.3 Gaps in Current Leukapheresis Technologies
4.2.4 Challenges
4.2.4.1 Infectious Disease Risks Related to Safety of Blood Transfusion in Emerging Economies
4.2.4.2 Donor Variability and Inconsistent Leukopak Quality
4.3 Unmet Needs & White Spaces
4.3.1 Unmet Needs in Leukapheresis Market
4.3.2 White Space Opportunities
4.4 Interconnected Markets & Cross-Sector Opportunities
4.4.1 Interconnected Markets
4.4.2 Cross-Sector Opportunities
4.5 Strategic Moves by Tier-1/2/3 Players
4.5.1 Strategic Moves by Tier 1/2/3 Players in Leukapheresis Market
5 Industry Trends
5.1 Porter’S Five Forces Analysis
5.1.1 Threat of New Entrants
5.1.2 Threat of Substitutes
5.1.3 Bargaining Power of Suppliers
5.1.4 Bargaining Power of Buyers
5.1.5 Intensity of Competitive Rivalry
5.2 Macroeconomic Outlook
5.2.1 Introduction
5.2.2 GDP Trends & Forecast
5.2.3 Trends in Global Healthcare Industry
5.2.4 Trends in Global Medical Device Industry
5.3 Supply Chain Analysis
5.4 Value Chain Analysis
5.5 Market Ecosystem
5.5.1 Leukapheresis Market Providers
5.5.2 End Users
5.5.3 Regulatory Bodies
5.6 Pricing Analysis (Leukopaks Market)
5.6.1 Average Selling Price Trend for Non-Mobilized Leukopaks, by Region, 2023-2025 (USD)
5.6.2 Average Selling Price Trend for Mobilized Leukopaks, by Region, 2023-2025 (USD)
5.7 Trade Analysis
5.7.1 Import Data for Hs Code 901890
5.7.2 Export Data for Hs Code 901890
5.8 Reimbursement Scenario
5.9 Key Conferences & Events (2026-2027)
5.10 Trends/Disruptions Impacting Customer Business
5.11 Investment & Funding Scenario
5.12 Case Study Analysis
5.13 Impact of 2025 US Tariff on Leukapheresis Market
5.13.1 Introduction
5.13.2 Key Tariff Rates
5.13.3 Price Impact Analysis
5.13.4 Impact on Regions
5.13.5 Impact on End-Use Segments
5.13.5.1 Leukapheresis
5.13.5.2 Leukopaks
5.1.1 Threat of New Entrants
5.1.2 Threat of Substitutes
5.1.3 Bargaining Power of Suppliers
5.1.4 Bargaining Power of Buyers
5.1.5 Intensity of Competitive Rivalry
5.2 Macroeconomic Outlook
5.2.1 Introduction
5.2.2 GDP Trends & Forecast
5.2.3 Trends in Global Healthcare Industry
5.2.4 Trends in Global Medical Device Industry
5.3 Supply Chain Analysis
5.4 Value Chain Analysis
5.5 Market Ecosystem
5.5.1 Leukapheresis Market Providers
5.5.2 End Users
5.5.3 Regulatory Bodies
5.6 Pricing Analysis (Leukopaks Market)
5.6.1 Average Selling Price Trend for Non-Mobilized Leukopaks, by Region, 2023-2025 (USD)
5.6.2 Average Selling Price Trend for Mobilized Leukopaks, by Region, 2023-2025 (USD)
5.7 Trade Analysis
5.7.1 Import Data for Hs Code 901890
5.7.2 Export Data for Hs Code 901890
5.8 Reimbursement Scenario
5.9 Key Conferences & Events (2026-2027)
5.10 Trends/Disruptions Impacting Customer Business
5.11 Investment & Funding Scenario
5.12 Case Study Analysis
5.13 Impact of 2025 US Tariff on Leukapheresis Market
5.13.1 Introduction
5.13.2 Key Tariff Rates
5.13.3 Price Impact Analysis
5.13.4 Impact on Regions
5.13.5 Impact on End-Use Segments
5.13.5.1 Leukapheresis
5.13.5.2 Leukopaks
6 Technological Advancements, AI-Drive Impact, Patents, and Innovations
6.1 Technology Analysis
6.1.1 Key Emerging Technologies
6.1.1.1 Automated & AI-Enabled Apheresis Systems
6.1.1.2 Closed-Loop & Gmp-Compliant Processing Systems
6.1.1.3 Cryopreservation & Cryo-Processed Leukopaks Technologies
6.1.2 Complementary Technologies
6.1.2.1 Cell Processing & Manufacturing Platforms (Cgt Ecosystem)
6.1.2.2 Digital Monitoring, Data Integration, and Workflow Software
6.1.3 Adjacent Technologies
6.1.3.1 Regenerative Medicine & Stem Cell Technologies
6.2 Technology/Product Roadmap
6.2.1 Near Term (2025-2027)
6.2.2 Mid Term (2028-2030)
6.2.3 Long Term (2030+)
6.3 Patent Analysis
6.3.1 Jurisdiction and Top Applicant Analysis
6.4 Future Applications
6.4.1 Cell & Gene Therapy (Car-T, Tcr, Nk Cells)
6.4.2 Decentralized & Point-of-Care Cell Collection
6.4.3 Stem Cell Transplantation & Regenerative Medicine
6.5 Impact of AI/Gen AI on Leukapheresis Market
6.5.1 Introduction
6.5.2 Market Potential of AI in Leukapheresis
6.5.3 AI Use Cases
6.5.4 Key Companies Implementing AI
6.1.1 Key Emerging Technologies
6.1.1.1 Automated & AI-Enabled Apheresis Systems
6.1.1.2 Closed-Loop & Gmp-Compliant Processing Systems
6.1.1.3 Cryopreservation & Cryo-Processed Leukopaks Technologies
6.1.2 Complementary Technologies
6.1.2.1 Cell Processing & Manufacturing Platforms (Cgt Ecosystem)
6.1.2.2 Digital Monitoring, Data Integration, and Workflow Software
6.1.3 Adjacent Technologies
6.1.3.1 Regenerative Medicine & Stem Cell Technologies
6.2 Technology/Product Roadmap
6.2.1 Near Term (2025-2027)
6.2.2 Mid Term (2028-2030)
6.2.3 Long Term (2030+)
6.3 Patent Analysis
6.3.1 Jurisdiction and Top Applicant Analysis
6.4 Future Applications
6.4.1 Cell & Gene Therapy (Car-T, Tcr, Nk Cells)
6.4.2 Decentralized & Point-of-Care Cell Collection
6.4.3 Stem Cell Transplantation & Regenerative Medicine
6.5 Impact of AI/Gen AI on Leukapheresis Market
6.5.1 Introduction
6.5.2 Market Potential of AI in Leukapheresis
6.5.3 AI Use Cases
6.5.4 Key Companies Implementing AI
7 Sustainability & Regulatory Behavior
7.1 Regulatory Landscape
7.1.1 Regulatory Framework
7.1.1.1 North America
7.1.1.2 Europe
7.1.1.3 Asia-Pacific
7.1.1.4 Latin America
7.1.1.5 Middle East & Africa
7.1.2 Regulatory Bodies, Government Agencies, and Other Organizations
7.1.3 Industry Standards
7.2 Sustainability Initiatives
7.2.1 Recycled and Eco-Friendly Materials for Leukapheresis
7.2.2 Sustainability Impact & Regulatory Policy Initiatives
7.2.3 Certifications, Labeling, and Eco-Standards
7.1.1 Regulatory Framework
7.1.1.1 North America
7.1.1.2 Europe
7.1.1.3 Asia-Pacific
7.1.1.4 Latin America
7.1.1.5 Middle East & Africa
7.1.2 Regulatory Bodies, Government Agencies, and Other Organizations
7.1.3 Industry Standards
7.2 Sustainability Initiatives
7.2.1 Recycled and Eco-Friendly Materials for Leukapheresis
7.2.2 Sustainability Impact & Regulatory Policy Initiatives
7.2.3 Certifications, Labeling, and Eco-Standards
8 Customer Landscape & Buyer Behavior
8.1 Key Stakeholders & Buying Criteria
8.1.1 Key Stakeholders in Buying Process
8.1.2 Buying Criteria
8.2 Customer Landscape & Buyer Behavior
8.2.1 Decision-Making Process
8.2.2 Adoption Barriers & Internal Challenges
8.2.3 Unmet Needs From Various End-Use Industries
8.2.4 Market Profitability
8.1.1 Key Stakeholders in Buying Process
8.1.2 Buying Criteria
8.2 Customer Landscape & Buyer Behavior
8.2.1 Decision-Making Process
8.2.2 Adoption Barriers & Internal Challenges
8.2.3 Unmet Needs From Various End-Use Industries
8.2.4 Market Profitability
9 Leukapheresis Market, by Product Type
9.1 Introduction
9.2 Disposables
9.2.1 Single-Use, Procedure-Driven Consumption to Boost Segment
9.2.2 Tubing Sets & Collection Bags
9.2.2.1 Rising Leukapheresis Procedure Volumes Driving Demand for Tubing Sets & Collection Bags
9.2.3 Filters & Membrane Consumables
9.2.3.1 Growing Adoption of Leukocyte Removal Filters in Inflammatory Disease Management
9.2.4 Collection Kits & Accessories
9.2.4.1 Increasing Leukapheresis and Leukopak Collection Activities Driving Demand for Collection Kits and Accessories
9.3 Devices
9.3.1 Centrifugal Devices
9.3.1.1 Increasing Installation in Hospitals to Drive Market
9.3.1.2 Global Volume Analysis: Centrifugal Devices Market (2024-2031)
9.3.2 Membrane Separators
9.3.2.1 Difficulty in Separating Large Volumes of Plasma to Limit Market
9.2 Disposables
9.2.1 Single-Use, Procedure-Driven Consumption to Boost Segment
9.2.2 Tubing Sets & Collection Bags
9.2.2.1 Rising Leukapheresis Procedure Volumes Driving Demand for Tubing Sets & Collection Bags
9.2.3 Filters & Membrane Consumables
9.2.3.1 Growing Adoption of Leukocyte Removal Filters in Inflammatory Disease Management
9.2.4 Collection Kits & Accessories
9.2.4.1 Increasing Leukapheresis and Leukopak Collection Activities Driving Demand for Collection Kits and Accessories
9.3 Devices
9.3.1 Centrifugal Devices
9.3.1.1 Increasing Installation in Hospitals to Drive Market
9.3.1.2 Global Volume Analysis: Centrifugal Devices Market (2024-2031)
9.3.2 Membrane Separators
9.3.2.1 Difficulty in Separating Large Volumes of Plasma to Limit Market
10 Leukapheresis Market, by Application
10.1 Introduction
10.2 Research Applications
10.2.1 Expanding Cell & Gene Therapy Pipeline to Drive the Segment
10.3 Therapeutic Applications
10.3.1 Increasing Adoption of Leukapheresis in Leukemia Management Driving Market Growth
10.2 Research Applications
10.2.1 Expanding Cell & Gene Therapy Pipeline to Drive the Segment
10.3 Therapeutic Applications
10.3.1 Increasing Adoption of Leukapheresis in Leukemia Management Driving Market Growth
11 Leukapheresis Market, by End User
11.1 Introduction
11.2 Blood Component Providers & Blood Centers
11.2.1 Rising Blood Donation and Transfusion Needs Driving Leukapheresis Demand
11.3 Hospitals & Transfusion Centers
11.3.1 High Procedural Volumes in Hospitals to Drive Leukapheresis Demand
11.4 Academic & Research Institutes
11.4.1 Increasing Academic-Industry Collaborations to Boost Market
11.5 Pharmaceutical & Biotechnology Companies
11.5.1 Growing Number of Clinical Trials to Boost Segment
11.2 Blood Component Providers & Blood Centers
11.2.1 Rising Blood Donation and Transfusion Needs Driving Leukapheresis Demand
11.3 Hospitals & Transfusion Centers
11.3.1 High Procedural Volumes in Hospitals to Drive Leukapheresis Demand
11.4 Academic & Research Institutes
11.4.1 Increasing Academic-Industry Collaborations to Boost Market
11.5 Pharmaceutical & Biotechnology Companies
11.5.1 Growing Number of Clinical Trials to Boost Segment
12 Leukopaks Market, by Type
12.1 Introduction
12.2 Mobilized Leukopaks
12.2.1 Increasing Use of Mobilized Leukopaks in Clinical Research to Drive Market
12.2.2 Global Volume Analysis: Mobilized Leukopaks Market (2024-2031)
12.3 Non-Mobilized Leukopaks
12.3.1 Adoption of Non-Mobilized Leukopaks Driven by Lower Cost and Cell Yield
12.3.2 Global Volume Analysis: Non-Mobilized Leukopaks Market (2024-2031)
12.4 Diseased Leukopaks
12.4.1 Increasing Demand for Disease-State Leukopaks in Advanced Therapeutic Research Driving Market Growth”
12.4.2 Global Volume Analysis: Diseased Leukopaks Market (2024-2031)
12.5 Isolated Pbmcs
12.5.1 Increasing Research Focus on Cell-Based Therapies to Fuel Market
12.5.2 Global Volume Analysis: Isolated Pbmcs Market (2024-2031)
12.2 Mobilized Leukopaks
12.2.1 Increasing Use of Mobilized Leukopaks in Clinical Research to Drive Market
12.2.2 Global Volume Analysis: Mobilized Leukopaks Market (2024-2031)
12.3 Non-Mobilized Leukopaks
12.3.1 Adoption of Non-Mobilized Leukopaks Driven by Lower Cost and Cell Yield
12.3.2 Global Volume Analysis: Non-Mobilized Leukopaks Market (2024-2031)
12.4 Diseased Leukopaks
12.4.1 Increasing Demand for Disease-State Leukopaks in Advanced Therapeutic Research Driving Market Growth”
12.4.2 Global Volume Analysis: Diseased Leukopaks Market (2024-2031)
12.5 Isolated Pbmcs
12.5.1 Increasing Research Focus on Cell-Based Therapies to Fuel Market
12.5.2 Global Volume Analysis: Isolated Pbmcs Market (2024-2031)
13 Leukopaks Market, by Indication
13.1 Introduction
13.2 Acute Lymphocytic Leukemia
13.2.1 Increasing Incidence of Acute Lymphocytic Leukemia Supporting Market Growth
13.3 Multiple Myeloma
13.3.1 Rising Multiple Myeloma Cases Driving Market Expansion
13.4 Non-Hodgkin’S Lymphoma
13.4.1 Development of Novel Therapies to Boost Market
13.5 Chronic Lymphocytic Leukemia
13.5.1 Growing Prevalence of Chronic Lymphocytic Leukemia Driving Segment Expansion
13.6 Pancreatic Cancer
13.6.1 Development of New Diagnostic Techniques to Drive Segment
13.7 Hepatocellular Carcinoma
13.7.1 Increasing Incidence of Viral Hepatitis to Fuel Segment
13.8 Other Indications
13.2 Acute Lymphocytic Leukemia
13.2.1 Increasing Incidence of Acute Lymphocytic Leukemia Supporting Market Growth
13.3 Multiple Myeloma
13.3.1 Rising Multiple Myeloma Cases Driving Market Expansion
13.4 Non-Hodgkin’S Lymphoma
13.4.1 Development of Novel Therapies to Boost Market
13.5 Chronic Lymphocytic Leukemia
13.5.1 Growing Prevalence of Chronic Lymphocytic Leukemia Driving Segment Expansion
13.6 Pancreatic Cancer
13.6.1 Development of New Diagnostic Techniques to Drive Segment
13.7 Hepatocellular Carcinoma
13.7.1 Increasing Incidence of Viral Hepatitis to Fuel Segment
13.8 Other Indications
14 Leukopaks Market, by End User
14.1 Introduction
14.2 Academic & Research Institutes
14.2.1 Increasing Industry-Academic Collaborations Driving Market Growth
14.3 Pharmaceutical & Biotechnology Companies
14.3.1 Rising Demand for Targeted Cell-Based Drug Development Driving Leukopak Adoption
14.4 Contract Research Organizations
14.4.1 Increasing Cro-Led Clinical Activities Driving Demand for Leukapheresis-Derived Materials
14.2 Academic & Research Institutes
14.2.1 Increasing Industry-Academic Collaborations Driving Market Growth
14.3 Pharmaceutical & Biotechnology Companies
14.3.1 Rising Demand for Targeted Cell-Based Drug Development Driving Leukopak Adoption
14.4 Contract Research Organizations
14.4.1 Increasing Cro-Led Clinical Activities Driving Demand for Leukapheresis-Derived Materials
15 Leukapheresis Market, by Region
15.1 Introduction
15.2 North America
15.2.1 Macroeconomic Outlook for North America
15.2.2 North America Volume Analysis: Leukopaks Type (2024-2031)
15.2.3 US
15.2.3.1 Strong Presence of Biopharmaceutical Leaders and Expanding Cell Therapy Ecosystem Driving Market Growth
15.2.4 Canada
15.2.4.1 Increasing Leukemia Incidence and Advancements in Car-T Therapies Supporting Market Growth in Canada
15.3 Europe
15.3.1 Macroeconomic Outlook for Europe
15.3.2 Europe Volume Analysis: Leukopaks Type (2024-2031)
15.3.3 Germany
15.3.3.1 Rising Healthcare Expenditure, Expanding Academic-Clinical Cell Therapy Ecosystem to Drive Market Growth
15.3.4 UK
15.3.4.1 Expanding Apheresis Capacity and Car-T Therapies Adoption to Support Market Growth
15.3.1 France
15.3.1.1 Centralized Car-T Delivery System and Strong Public Reimbursement to Propel Market Growth
15.3.2 Italy
15.3.2.1 Rising Elderly Patient Pool and High Cancer Incidence to Drive Market Growth
15.3.3 Spain
15.3.3.1 Rising Hematologic Cancer Burden to Support Market Growth
15.3.4 Belgium
15.3.4.1 Strong Clinical Research Ecosystem and Structured Reimbursement Framework to Boost the Market
15.3.5 Netherlands
15.3.5.1 Strong Healthcare Infrastructure and Aging Population to Drive Market
15.3.6 Poland
15.3.6.1 Rise in Cancer Incidence to Boost the Market
15.3.7 Switzerland
15.3.7.1 Early Adoption of Cell Therapies to Drive Market Demand
15.3.8 Rest of Europe
15.4 Asia-Pacific
15.4.1 Macroeconomic Outlook for Asia-Pacific
15.4.2 Asia-Pacific Volume Analysis: Leukopaks Type (2024-2031)
15.4.3 China
15.4.3.1 Increasing Hematologic Cancer Burden, Car-T Expansion, and Biotech Investments Driving Leukapheresis Growth in China
15.4.4 Japan
15.4.4.1 Moderate-to-High Healthcare Expenditure Supporting Leukapheresis Market Growth
15.4.5 India
15.4.5.1 Rising Government Investment in Healthcare to Drive Market Growth
15.4.6 Australia
15.4.6.1 Clinical Integration of Car-T Therapies in Hospitals as Core Growth Driver for Leukapheresis in Australia
15.4.7 South Korea
15.4.7.1 Integration of Digital and Automated Cell Processing Technologies Driving Growth in the Leukapheresis Market
15.4.8 New Zealand
15.4.8.1 Strengthening Therapeutic Apheresis Infrastructure as A Core Growth Driver for the New Zealand Leukapheresis Market
15.4.9 Thailand
15.4.9.1 Rising Oncology Demand for Cell-Based Therapies Driving Leukapheresis Market Growth
15.4.10 Rest of Asia-Pacific
15.5 Latin America
15.5.1 Latin America Volume Analysis: Leukopaks Type (2024-2031)
15.5.2 Brazil
15.5.2.1 Role of Blood Donation, Transplant Activity, and Cell Therapy Expansion in Driving the Leukapheresis and Leukopak Market
15.5.3 Mexico
15.5.3.1 Emerging Car-T Therapy and Cost-Driven Leukemia Care Market in Mexico
15.5.4 Rest of Latin America
15.6 Middle East & Africa
15.6.1 Macroeconomic Outlook for Middle East & Africa
15.6.2 Middle East & Africa Volume Analysis: Leukopaks Type (2024-2031)
15.6.3 GCC Countries
15.6.3.1 Kingdom of Saudi Arabia (KSA)
15.6.3.1.1 Transforming Clinical Research in Saudi Arabia Through Healthcare Innovation Initiatives
15.6.3.2 United Arab Emirates (UAE)
15.6.3.2.1 Emergence as A Regional Hub for Advanced Precision Medicine
15.6.3.3 Other GCC Countries
15.6.4 Rest of Middle East & Africa
15.2 North America
15.2.1 Macroeconomic Outlook for North America
15.2.2 North America Volume Analysis: Leukopaks Type (2024-2031)
15.2.3 US
15.2.3.1 Strong Presence of Biopharmaceutical Leaders and Expanding Cell Therapy Ecosystem Driving Market Growth
15.2.4 Canada
15.2.4.1 Increasing Leukemia Incidence and Advancements in Car-T Therapies Supporting Market Growth in Canada
15.3 Europe
15.3.1 Macroeconomic Outlook for Europe
15.3.2 Europe Volume Analysis: Leukopaks Type (2024-2031)
15.3.3 Germany
15.3.3.1 Rising Healthcare Expenditure, Expanding Academic-Clinical Cell Therapy Ecosystem to Drive Market Growth
15.3.4 UK
15.3.4.1 Expanding Apheresis Capacity and Car-T Therapies Adoption to Support Market Growth
15.3.1 France
15.3.1.1 Centralized Car-T Delivery System and Strong Public Reimbursement to Propel Market Growth
15.3.2 Italy
15.3.2.1 Rising Elderly Patient Pool and High Cancer Incidence to Drive Market Growth
15.3.3 Spain
15.3.3.1 Rising Hematologic Cancer Burden to Support Market Growth
15.3.4 Belgium
15.3.4.1 Strong Clinical Research Ecosystem and Structured Reimbursement Framework to Boost the Market
15.3.5 Netherlands
15.3.5.1 Strong Healthcare Infrastructure and Aging Population to Drive Market
15.3.6 Poland
15.3.6.1 Rise in Cancer Incidence to Boost the Market
15.3.7 Switzerland
15.3.7.1 Early Adoption of Cell Therapies to Drive Market Demand
15.3.8 Rest of Europe
15.4 Asia-Pacific
15.4.1 Macroeconomic Outlook for Asia-Pacific
15.4.2 Asia-Pacific Volume Analysis: Leukopaks Type (2024-2031)
15.4.3 China
15.4.3.1 Increasing Hematologic Cancer Burden, Car-T Expansion, and Biotech Investments Driving Leukapheresis Growth in China
15.4.4 Japan
15.4.4.1 Moderate-to-High Healthcare Expenditure Supporting Leukapheresis Market Growth
15.4.5 India
15.4.5.1 Rising Government Investment in Healthcare to Drive Market Growth
15.4.6 Australia
15.4.6.1 Clinical Integration of Car-T Therapies in Hospitals as Core Growth Driver for Leukapheresis in Australia
15.4.7 South Korea
15.4.7.1 Integration of Digital and Automated Cell Processing Technologies Driving Growth in the Leukapheresis Market
15.4.8 New Zealand
15.4.8.1 Strengthening Therapeutic Apheresis Infrastructure as A Core Growth Driver for the New Zealand Leukapheresis Market
15.4.9 Thailand
15.4.9.1 Rising Oncology Demand for Cell-Based Therapies Driving Leukapheresis Market Growth
15.4.10 Rest of Asia-Pacific
15.5 Latin America
15.5.1 Latin America Volume Analysis: Leukopaks Type (2024-2031)
15.5.2 Brazil
15.5.2.1 Role of Blood Donation, Transplant Activity, and Cell Therapy Expansion in Driving the Leukapheresis and Leukopak Market
15.5.3 Mexico
15.5.3.1 Emerging Car-T Therapy and Cost-Driven Leukemia Care Market in Mexico
15.5.4 Rest of Latin America
15.6 Middle East & Africa
15.6.1 Macroeconomic Outlook for Middle East & Africa
15.6.2 Middle East & Africa Volume Analysis: Leukopaks Type (2024-2031)
15.6.3 GCC Countries
15.6.3.1 Kingdom of Saudi Arabia (KSA)
15.6.3.1.1 Transforming Clinical Research in Saudi Arabia Through Healthcare Innovation Initiatives
15.6.3.2 United Arab Emirates (UAE)
15.6.3.2.1 Emergence as A Regional Hub for Advanced Precision Medicine
15.6.3.3 Other GCC Countries
15.6.4 Rest of Middle East & Africa
16 Competitive Landscape
16.1 Introduction
16.2 Key Player Competitive Strategies/Right to Win, 2022-2026
16.2.1 Overview of Strategies Adopted by Key Players in Leukapheresis Market
16.3 Revenue Analysis, 2023-2025
16.3.1 Leukapheresis Market: Revenue Analysis
16.3.2 Leukopaks Market: Revenue Analysis
16.4 Market Share Analysis, 2025
16.4.1 Leukapheresis Market: Share Analysis
16.4.2 Leukopaks Market: Share Analysis
16.5 Company Evaluation Matrix: Key Players, 2025
16.5.1 Leukopaks Market
16.5.1.1 Stars
16.5.1.2 Emerging Leaders
16.5.1.3 Pervasive Players
16.5.1.4 Participants
16.5.1.5 Company Footprint: Key Players, 2025
16.5.1.5.1 Company Footprint
16.5.1.5.2 by Region Footprint
16.5.1.5.3 by Product Type Footprint
16.6 Company Evaluation Matrix: Startups/SMEs, 2025
16.6.1 Leukopaks Market
16.6.1.1 Progressive Companies
16.6.1.2 Responsive Companies
16.6.1.3 Dynamic Companies
16.6.1.4 Starting Blocks
16.6.1.5 Competitive Benchmarking: Startups/SMEs, 2025
16.6.1.5.1 Detailed List of Key Startups/SMEs
16.6.1.5.2 Competitive Benchmarking of Key Startups/SMEs
16.7 Company Valuation and Financial Metrics
16.7.1 Financial Metrics: Leukapheresis Market
16.7.2 Company Valuation : Leukapheresis Market
16.7.3 Financial Metrics: Leukopaks Market
16.7.4 Company Valuation: Leukopaks Market
16.8 Leukopaks Brand/Product Comparison
16.9 Leukaphereis Brand/Product Comparison
16.10 Competitive Scenario
16.10.1 Leukapheresis Market
16.10.1.1 Product Launches & Approvals
16.10.1.2 Deals
16.10.1.3 Expansions
16.10.2 Leukopaks Market
16.10.2.1 Product Launches & Approvals
16.10.2.2 Deals
16.10.2.3 Expansions
16.2 Key Player Competitive Strategies/Right to Win, 2022-2026
16.2.1 Overview of Strategies Adopted by Key Players in Leukapheresis Market
16.3 Revenue Analysis, 2023-2025
16.3.1 Leukapheresis Market: Revenue Analysis
16.3.2 Leukopaks Market: Revenue Analysis
16.4 Market Share Analysis, 2025
16.4.1 Leukapheresis Market: Share Analysis
16.4.2 Leukopaks Market: Share Analysis
16.5 Company Evaluation Matrix: Key Players, 2025
16.5.1 Leukopaks Market
16.5.1.1 Stars
16.5.1.2 Emerging Leaders
16.5.1.3 Pervasive Players
16.5.1.4 Participants
16.5.1.5 Company Footprint: Key Players, 2025
16.5.1.5.1 Company Footprint
16.5.1.5.2 by Region Footprint
16.5.1.5.3 by Product Type Footprint
16.6 Company Evaluation Matrix: Startups/SMEs, 2025
16.6.1 Leukopaks Market
16.6.1.1 Progressive Companies
16.6.1.2 Responsive Companies
16.6.1.3 Dynamic Companies
16.6.1.4 Starting Blocks
16.6.1.5 Competitive Benchmarking: Startups/SMEs, 2025
16.6.1.5.1 Detailed List of Key Startups/SMEs
16.6.1.5.2 Competitive Benchmarking of Key Startups/SMEs
16.7 Company Valuation and Financial Metrics
16.7.1 Financial Metrics: Leukapheresis Market
16.7.2 Company Valuation : Leukapheresis Market
16.7.3 Financial Metrics: Leukopaks Market
16.7.4 Company Valuation: Leukopaks Market
16.8 Leukopaks Brand/Product Comparison
16.9 Leukaphereis Brand/Product Comparison
16.10 Competitive Scenario
16.10.1 Leukapheresis Market
16.10.1.1 Product Launches & Approvals
16.10.1.2 Deals
16.10.1.3 Expansions
16.10.2 Leukopaks Market
16.10.2.1 Product Launches & Approvals
16.10.2.2 Deals
16.10.2.3 Expansions
17 Company Profiles
17.1 Leukapheresis Products Market: Key Players
17.1.1 Terumo Corporation
17.1.1.1 Business Overview
17.1.1.2 Products Offered
17.1.1.3 Recent Developments
17.1.1.3.1 Product Launches & Approvals
17.1.1.3.2 Deals
17.1.1.3.3 Expansions
17.1.1.4 The Analyst's View
17.1.1.4.1 Right to Win
17.1.1.4.2 Strategic Choices
17.1.1.4.3 Weaknesses & Competitive Threats
17.1.2 Fresenius SE & Co. Kgaa
17.1.2.1 Business Overview
17.1.2.2 Products Offered
17.1.2.3 Recent Developments
17.1.2.3.1 Product Launches & Approvals
17.1.2.3.2 Deals
17.1.2.3.3 Other Developments
17.1.2.4 The Analyst's View
17.1.2.4.1 Right to Win
17.1.2.4.2 Strategic Choices
17.1.2.4.3 Weaknesses & Competitive Threats
17.1.3 Haemonetics Corporation
17.1.3.1 Business Overview
17.1.3.2 Products Offered
17.1.3.3 Recent Developments
17.1.3.3.1 Product Launches & Approvals
17.1.3.3.2 Deals
17.1.3.4 The Analyst's View
17.1.3.4.1 Right to Win
17.1.3.4.2 Strategic Choices
17.1.3.4.3 Weaknesses & Competitive Threats
17.1.4 Nikkiso Co. Ltd.
17.1.4.1 Business Overview
17.1.4.2 Products Offered
17.1.4.3 Recent Developments
17.1.4.3.1 Other Developments
17.1.4.4 The Analyst's View
17.1.4.4.1 Right to Win
17.1.4.4.2 Strategic Choices
17.1.4.4.3 Weaknesses & Competitive Threats
17.1.5 Sumitomo Bakelite Co. Ltd.
17.1.5.1 Business Overview
17.1.5.2 Products Offered
17.1.5.3 The Analyst's View
17.1.5.3.1 Right to Win
17.1.5.3.2 Strategic Choices
17.1.5.3.3 Weaknesses & Competitive Threats
17.1.6 Danaher Corporation
17.1.6.1 Business Overview
17.1.6.2 Products Offered
17.1.7 Otsuka Holdings Co. Ltd.
17.1.7.1 Business Overview
17.1.7.2 Products Offered
17.1.8 Asahi Kasei Medical Co. Ltd.
17.1.8.1 Business Overview
17.1.8.2 Products Offered
17.1.8.3 Recent Developments
17.1.8.3.1 Other Developments
17.1.9 Macopharma SA
17.1.9.1 Business Overview
17.1.9.2 Products Offered
17.1.10 Medica Spa
17.1.10.1 Business Overview
17.1.10.2 Products Offered
17.2 Leukapheresis Products Market: Other Players
17.2.1 Polymed
17.2.2 Puriblood Medical
17.2.3 Guangzhou Daji Medical Science and Technology Co. Ltd.
17.2.4 Safetran Biomedical Inc.
17.2.5 Mitra Industries Private Limited
17.3 Leukopaks Market: Key Players
17.3.1 Lonza
17.3.1.1 Business Overview
17.3.1.2 Products Offered
17.3.1.3 Recent Developments
17.3.1.3.1 Deals
17.3.1.4 The Analyst's View
17.3.1.4.1 Right to Win
17.3.1.4.2 Strategic Choices
17.3.1.4.3 Weaknesses and Competitive Threats
17.3.2 Grifols
17.3.2.1 Business Overview
17.3.2.2 Products Offered
17.3.3 Charles River Laboratories
17.3.3.1 Business Overview
17.3.3.2 Products Offered
17.3.3.3 Recent Developments
17.3.3.3.1 Product Launches & Approvals
17.3.3.3.2 Deals
17.3.3.3.3 Expansions
17.3.4 Cellex Cell Professionals
17.3.4.1 Business Overview
17.3.4.2 Products Offered
17.3.4.3 Recent Developments
17.3.4.3.1 Deals
17.3.4.3.2 Expansions
17.3.5 Stemcell Technologies
17.3.5.1 Business Overview
17.3.5.2 Products Offered
17.3.6 Bioivt
17.3.6.1 Business Overview
17.3.6.2 Products Offered
17.3.6.3 Recent Developments
17.3.6.3.1 Product Launches & Approvals
17.3.6.3.2 Deals
17.3.6.3.3 Expansions
17.3.7 Discovery Life Sciences
17.3.7.1 Business Overview
17.3.7.2 Products Offered
17.3.7.3 Recent Developments
17.3.7.3.1 Product Launches & Approvals
17.3.7.3.2 Deals
17.3.7.3.3 Expansions
17.3.8 Miltenyi Biotec
17.3.8.1 Business Overview
17.3.8.2 Products Offered
17.3.9 Stemvivo Inc.
17.3.9.1 Business Overview
17.3.9.2 Products Offered
17.3.10 Cgt Global
17.3.10.1 Business Overview
17.3.10.2 Products Offered
17.3.10.3 Recent Developments
17.3.10.3.1 Product Launches & Approvals
17.3.11 Sanguine Biosciences
17.3.11.1 Business Overview
17.3.11.2 Products Offered
17.3.11.3 Recent Developments
17.3.11.3.1 Product Launches & Approvals
17.4 Leukopaks Market: Other Players
17.4.1 Biomex GmbH
17.4.2 Accegen
17.4.3 Excellos
17.4.4 First Choice Bio Inc.
17.4.5 Organa Bio
17.4.6 Human Cells Bio
17.1.1 Terumo Corporation
17.1.1.1 Business Overview
17.1.1.2 Products Offered
17.1.1.3 Recent Developments
17.1.1.3.1 Product Launches & Approvals
17.1.1.3.2 Deals
17.1.1.3.3 Expansions
17.1.1.4 The Analyst's View
17.1.1.4.1 Right to Win
17.1.1.4.2 Strategic Choices
17.1.1.4.3 Weaknesses & Competitive Threats
17.1.2 Fresenius SE & Co. Kgaa
17.1.2.1 Business Overview
17.1.2.2 Products Offered
17.1.2.3 Recent Developments
17.1.2.3.1 Product Launches & Approvals
17.1.2.3.2 Deals
17.1.2.3.3 Other Developments
17.1.2.4 The Analyst's View
17.1.2.4.1 Right to Win
17.1.2.4.2 Strategic Choices
17.1.2.4.3 Weaknesses & Competitive Threats
17.1.3 Haemonetics Corporation
17.1.3.1 Business Overview
17.1.3.2 Products Offered
17.1.3.3 Recent Developments
17.1.3.3.1 Product Launches & Approvals
17.1.3.3.2 Deals
17.1.3.4 The Analyst's View
17.1.3.4.1 Right to Win
17.1.3.4.2 Strategic Choices
17.1.3.4.3 Weaknesses & Competitive Threats
17.1.4 Nikkiso Co. Ltd.
17.1.4.1 Business Overview
17.1.4.2 Products Offered
17.1.4.3 Recent Developments
17.1.4.3.1 Other Developments
17.1.4.4 The Analyst's View
17.1.4.4.1 Right to Win
17.1.4.4.2 Strategic Choices
17.1.4.4.3 Weaknesses & Competitive Threats
17.1.5 Sumitomo Bakelite Co. Ltd.
17.1.5.1 Business Overview
17.1.5.2 Products Offered
17.1.5.3 The Analyst's View
17.1.5.3.1 Right to Win
17.1.5.3.2 Strategic Choices
17.1.5.3.3 Weaknesses & Competitive Threats
17.1.6 Danaher Corporation
17.1.6.1 Business Overview
17.1.6.2 Products Offered
17.1.7 Otsuka Holdings Co. Ltd.
17.1.7.1 Business Overview
17.1.7.2 Products Offered
17.1.8 Asahi Kasei Medical Co. Ltd.
17.1.8.1 Business Overview
17.1.8.2 Products Offered
17.1.8.3 Recent Developments
17.1.8.3.1 Other Developments
17.1.9 Macopharma SA
17.1.9.1 Business Overview
17.1.9.2 Products Offered
17.1.10 Medica Spa
17.1.10.1 Business Overview
17.1.10.2 Products Offered
17.2 Leukapheresis Products Market: Other Players
17.2.1 Polymed
17.2.2 Puriblood Medical
17.2.3 Guangzhou Daji Medical Science and Technology Co. Ltd.
17.2.4 Safetran Biomedical Inc.
17.2.5 Mitra Industries Private Limited
17.3 Leukopaks Market: Key Players
17.3.1 Lonza
17.3.1.1 Business Overview
17.3.1.2 Products Offered
17.3.1.3 Recent Developments
17.3.1.3.1 Deals
17.3.1.4 The Analyst's View
17.3.1.4.1 Right to Win
17.3.1.4.2 Strategic Choices
17.3.1.4.3 Weaknesses and Competitive Threats
17.3.2 Grifols
17.3.2.1 Business Overview
17.3.2.2 Products Offered
17.3.3 Charles River Laboratories
17.3.3.1 Business Overview
17.3.3.2 Products Offered
17.3.3.3 Recent Developments
17.3.3.3.1 Product Launches & Approvals
17.3.3.3.2 Deals
17.3.3.3.3 Expansions
17.3.4 Cellex Cell Professionals
17.3.4.1 Business Overview
17.3.4.2 Products Offered
17.3.4.3 Recent Developments
17.3.4.3.1 Deals
17.3.4.3.2 Expansions
17.3.5 Stemcell Technologies
17.3.5.1 Business Overview
17.3.5.2 Products Offered
17.3.6 Bioivt
17.3.6.1 Business Overview
17.3.6.2 Products Offered
17.3.6.3 Recent Developments
17.3.6.3.1 Product Launches & Approvals
17.3.6.3.2 Deals
17.3.6.3.3 Expansions
17.3.7 Discovery Life Sciences
17.3.7.1 Business Overview
17.3.7.2 Products Offered
17.3.7.3 Recent Developments
17.3.7.3.1 Product Launches & Approvals
17.3.7.3.2 Deals
17.3.7.3.3 Expansions
17.3.8 Miltenyi Biotec
17.3.8.1 Business Overview
17.3.8.2 Products Offered
17.3.9 Stemvivo Inc.
17.3.9.1 Business Overview
17.3.9.2 Products Offered
17.3.10 Cgt Global
17.3.10.1 Business Overview
17.3.10.2 Products Offered
17.3.10.3 Recent Developments
17.3.10.3.1 Product Launches & Approvals
17.3.11 Sanguine Biosciences
17.3.11.1 Business Overview
17.3.11.2 Products Offered
17.3.11.3 Recent Developments
17.3.11.3.1 Product Launches & Approvals
17.4 Leukopaks Market: Other Players
17.4.1 Biomex GmbH
17.4.2 Accegen
17.4.3 Excellos
17.4.4 First Choice Bio Inc.
17.4.5 Organa Bio
17.4.6 Human Cells Bio
18 Research Methodology
18.1 Research Data
18.1.1 Secondary Data
18.1.1.1 Key Data From Secondary Sources
18.2 Market Size Estimation: Leukapheresis Market
18.3 Market Growth Rate Projections
18.4 Data Triangulation
18.5 Research Assumptions
18.5.1 Growth Rate Assumptions
18.6 Risk Assessment
18.7 Limitations
18.7.1 Methodology-Related Limitations
18.7.2 Scope-Related Limitations
18.8 Research Limitations
18.9 Risk Analysis
18.1.1 Secondary Data
18.1.1.1 Key Data From Secondary Sources
18.2 Market Size Estimation: Leukapheresis Market
18.3 Market Growth Rate Projections
18.4 Data Triangulation
18.5 Research Assumptions
18.5.1 Growth Rate Assumptions
18.6 Risk Assessment
18.7 Limitations
18.7.1 Methodology-Related Limitations
18.7.2 Scope-Related Limitations
18.8 Research Limitations
18.9 Risk Analysis
19 Appendix
19.1 Discussion Guide
19.2 Knowledgestore: The Subscription Portal
19.3 Customization Options
19.3.1 Company Information
19.3.2 Geographic Analysis
19.3.3 Regional/Country-Level Market Share Analysis
19.3.4 Country-Level Volume Analysis
19.3.5 Any Consults/Custom Requirements as Per Client Request
19.4 Related Reports
19.5 Author Details
19.2 Knowledgestore: The Subscription Portal
19.3 Customization Options
19.3.1 Company Information
19.3.2 Geographic Analysis
19.3.3 Regional/Country-Level Market Share Analysis
19.3.4 Country-Level Volume Analysis
19.3.5 Any Consults/Custom Requirements as Per Client Request
19.4 Related Reports
19.5 Author Details
- Terumo Corporation
- Fresenius SE & Co. Kgaa
- Haemonetics Corporation
- Nikkiso Co. Ltd.
- Sumitomo Bakelite Co. Ltd.
- Danaher Corporation
- Otsuka Holdings Co. Ltd.
- Asahi Kasei Medical Co. Ltd.
- Macopharma SA
- Medica Spa
- Polymed
- Puriblood Medical
- Guangzhou Daji Medical Science and Technology Co. Ltd.
- Safetran Biomedical Inc.
- Mitra Industries Private Limited
- Lonza
- Grifols
- Charles River Laboratories
- Cellex Cell Professionals
- Stemcell Technologies
- Bioivt
- Discovery Life Sciences
- Miltenyi Biotec
- Stemvivo Inc.
- Cgt Global
- Sanguine Biosciences
- Biomex GmbH
- Accegen
- Excellos
- First Choice Bio Inc.
- Organa Bio
- Human Cells Bio
List of Tables
Table 1 Leukapheresis Market: Inclusions & Exclusions
Table 2 Exchange Rates Utilized for Conversion to USD
Table 3 Cost of Leukopaks, by Type
Table 4 Donor Selection Criteria
Table 5 Frequency of Blood Donation From Healthy Donors
Table 6 Leukapheresis Market: Porter’S Five Forces Analysis
Table 7 GDP Change, by Key Country, 2021-2030 (USD Billion)
Table 8 List of Key Leukapheresis Devices + Disposables Manufacturers
Table 9 List of Key Leukopaks Manufacturers
Table 10 List of Key End Users
Table 11 List of Key Regulatory Bodies
Table 12 Average Selling Price of Non-Mobilized Leukopaks, 2025 (USD)
Table 13 Average Selling Price of Mobilized Leukopaks, 2025 (USD)
Table 14 Average Selling Price of Diseased Leukopaks, 2025 (USD)
Table 15 Average Selling Price of Isolated Pbmcs, 2025 (USD)
Table 16 Import Data for Hs Code 901890-Compliant Products, by Country, 2021-2025 (USD Thousand)
Table 17 Export Data for Hs Code 901890-Compliant Products, by Country, 2021-2025 (USD Thousand)
Table 18 Leukapheresis Market: Major Conferences & Events in 2026-2027
Table 19 Case Study 1: Rapid Cytoreduction in Pediatric Acute Leukemia Using Leukapheresis
Table 20 Case Study 2: Global Cell Therapy Trial Enabled by Leukapheresis Integration
Table 21 Case Study 3: Therapeutic Leukapheresis in Severe Pneumonia With Hyperleukocytosis
Table 22 US-Adjusted Reciprocal Tariff Rates, 2024
Table 23 Key Product-Related Tariff Effective
Table 24 North America: Impact of US Tariffs
Table 25 Asia-Pacific: Impact of US Tariffs
Table 26 Europe: Impact of US Tariffs
Table 27 Latin America: Impact of US Tariffs
Table 28 Leukapheresis Market: Key Patents, 2023-2025
Table 29 North America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 30 Europe: Regulatory Bodies, Government Agencies, and Other Organizations
Table 31 Asia-Pacific: Regulatory Bodies, Government Agencies, and Other Organizations
Table 32 Latin America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 33 Middle East & Africa: Regulatory Bodies, Government Agencies, and Other Organizations
Table 34 Influence of Stakeholders on Buying Process of Leukopaks
Table 35 Key Buying Criteria for Leukopaks, by Type
Table 36 Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 37 Disposables: Leukapheresis Market, by Product Type 2024-2031 (USD Million)
Table 38 Leukapheresis Disposable Products Market, by Country, 2024-2031 (USD Million)
Table 39 Tubing Sets & Collection Bags Market, by Type, 2024-2031 (USD Million)
Table 40 Commercially Available Filters & Membrane Consumables
Table 41 Filters & Membrane Consumables Market, by Type, 2024-2031 (USD Million)
Table 42 Commercially Available Collection Kits & Accessories
Table 43 Collection Kits & Accessories Market, by Type,2024-2031 (USD Million)
Table 44 Leukapheresis Devices Market, by Type, 2024-2031 (USD Million)
Table 45 Centrifugal Devices Available
Table 46 Centrifugal Devices Market, by Country, 2024-2031 (USD Million)
Table 47 Centrifugal Devices Volume Market, 2024-2031 (Units Sold)
Table 48 Membrane Separators Available
Table 49 Membrane Separators Market, by Country, 2024-2031 (USD Million)
Table 50 Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 51 Companies Developing Fda-Approved Car-T Cell Therapies
Table 52 Leukapheresis Market in Research Applications, by Country, 2024-2031 (USD Million)
Table 53 Leukapheresis Market in Therapeutic Applications, by Country, 2024-2031 (USD Million)
Table 54 Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 55 Leukapheresis Market for Blood Component Providers & Blood Centers, by Country, 2024-2031 (USD Million)
Table 56 Leukapheresis Market for Hospitals & Transfusion Centers, by Country, 2024-2031 (USD Million)
Table 57 Leukapheresis Market for Academic & Research Institutes, by Country, 2024-2031 (USD Million)
Table 58 Car-T Cell Therapy Under Clinical Trials
Table 59 Leukapheresis Products Market for Pharmaceutical & Biotechnology Companies, by Country, 2024-2031 (USD Million)
Table 60 Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 61 Leukopaks Market, by Country, 2024-2031 (USD Million)
Table 62 Mobilized Leukopaks Market, by Country, 2024-2031 (USD Million)
Table 63 Mobilized Leukopaks Market Volume, by Region, 2024-2031 (No. of Bags)
Table 64 Number of Cells in Non-Mobilized Leukopaks
Table 65 Comparative Analysis of Mobilized and Non-Mobilized Leukopaks
Table 66 Composition of Mobilized and Non-Mobilized Leukopaks
Table 67 Non-Mobilized Leukopaks Market, by Country, 2024-2031 (USD Million)
Table 68 Non-Mobilized Leukopaks Market Volume, by Region, 2024-2031 (No. of Bags)
Table 69 Diseased Cell Leukopaks and Their Role in Cell Therapy
Table 70 Diseased Leukopaks Market, by Country, 2024-2031 (USD Million)
Table 71 Diseased Leukopaks Market Volume, by Region, 2024-2031 (No. of Bags)
Table 72 Immune Cell Types and Targeted Diseases
Table 73 Isolated Pbmcs Market, by Country, 2024-2031 (USD Million)
Table 74 Isolated Pbmcs Market Volume, by Region, 2024-2031 (No. of Bags)
Table 75 Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 76 Leukopaks Market for Acute Lymphocytic Leukemia, by Country, 2024-2031 (USD Million)
Table 77 Leukopaks Market for Multiple Myeloma, by Country, 2024-2031 (USD Million)
Table 78 Leukopaks Market for Non-Hodgkin’S Lymphoma, by Country, 2024-2031 (USD Million)
Table 79 Leukopaks Market for Chronic Lymphocytic Leukemia, by Country, 2024-2031 (USD Million)
Table 80 Leukopaks Market for Pancreatic Cancer, by Country, 2024-2031 (USD Million)
Table 81 Leukopaks Market for Hepatocellular Carcinoma, by Country, 2024-2031 (USD Million)
Table 82 Leukopaks Market for Other Indications, by Country, 2024-2031 (USD Million)
Table 83 Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 84 Leukopaks Market for Academic & Research Institutes, by Country, 2024-2031 (USD Million)
Table 85 Leukopaks Market for Pharmaceutical & Biotechnology Companies, by Country, 2024-2031 (USD Million)
Table 86 Leukopaks Market for Contract Research Organizations, by Country, 2024-2031 (USD Million)
Table 87 Leukapheresis Products Market, by Region, 2024-2031 (USD Million)
Table 88 Leukopaks Market, by Region, 2024-2031 (USD Million)
Table 89 Major Leukapheresis Market Players in North America
Table 90 North America: Leukapheresis Market, by Country, 2024-2031 (USD Million)
Table 91 North America: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 92 North America: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 93 North America: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 94 North America: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 95 North America: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 96 North America: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 97 US: Key Macroindicators
Table 98 US: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 99 US: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 100 US: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 101 US: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 102 US: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 103 US: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 104 Canada: Key Macroindicators
Table 105 Canada: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 106 Canada: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 107 Canada: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 108 Canada: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 109 Canada: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 110 Canada: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 111 Europe: Leukopaks Market, by Leukopak Type, 2024-2031 (Million Unit Bags)
Table 112 Europe: Leukapheresis Market, by Country, 2024-2031 (USD Million)
Table 113 Europe: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 114 Europe: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 115 Europe: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 116 Europe: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 117 Europe: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 118 Europe: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 119 Germany: Key Macroindicators
Table 120 Germany: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 121 Germany: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 122 Germany: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 123 Germany: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 124 Germany: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 125 Germany: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 126 UK: Key Macroindicators
Table 127 UK: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 128 UK: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 129 UK: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 130 UK: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 131 UK: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 132 UK: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 133 France: Key Macroindicators
Table 134 Spain: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 135 Spain: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 136 Spain: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 137 Spain: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 138 Italy: Key Macroindicators
Table 139 Italy: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 140 Italy: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 141 Italy: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 142 Italy: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 143 Italy: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 144 Italy: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 145 Spain: Key Macroindicators
Table 146 Netherlands: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 147 Netherlands: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 148 Netherlands: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 149 Netherlands: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 150 Netherlands: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 151 Netherlands: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 152 Poland: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 153 Poland: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 154 Poland: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 155 Poland: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 156 Poland: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 157 Poland: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 158 Switzerland: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 159 Switzerland: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 160 Switzerland: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 161 Switzerland: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 162 Switzerland: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 163 Switzerland: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 164 Rest of Europe: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 165 Rest of Europe: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 166 Rest of Europe: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 167 Rest of Europe: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 168 Rest of Europe: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 169 Rest of Europe: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 170 Asia-Pacific: Leukapheresis Market, by Country, 2024-2031 (USD Million)
Table 171 Asia-Pacific: Leukopak Products Market, by Country, 2024-2031 (USD Million)
Table 172 Asia-Pacific: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 173 Asia-Pacific: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 174 Asia-Pacific: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 175 Asia-Pacific: Leukopaks Market, by Country, 2024-2031 (USD Million)
Table 176 Asia-Pacific: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 177 Asia-Pacific: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 178 Asia-Pacific: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 179 Asia-Pacific: Leukopaks Market, by Leukopak Type, 2024-2031 (Million Unit Bags)
Table 180 China: Key Macroindicators
Table 181 China: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 182 China: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 183 China: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 184 China: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 185 China: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 186 China: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 187 Japan: Key Macroindicators
Table 188 Japan: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 189 Japan: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 190 Japan: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 191 Japan: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 192 Japan: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 193 Japan: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 194 India: Key Macroindicators
Table 195 India: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 196 India: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 197 India: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 198 India: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 199 India: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 200 India: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 201 Australia: Key Macroindicators
Table 202 Australia: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 203 Australia: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 204 Australia: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 205 Australia: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 206 Australia: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 207 Australia: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 208 South Korea: Key Macroindicators
Table 209 South Korea: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 210 South Korea: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 211 South Korea: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 212 South Korea: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 213 South Korea: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 214 South Korea: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 215 New Zealand: Key Macroindicators
Table 216 New Zealand: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 217 New Zealand: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 218 New Zealand: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 219 New Zealand: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 220 New Zealand: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 221 New Zealand: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 222 Thailand: Key Macroindicators
Table 223 Thailand: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 224 Thailand: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 225 Thailand: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 226 Thailand: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 227 Thailand: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 228 Thailand: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 229 RoAPAC: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 230 RoAPAC: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 231 RoAPAC: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 232 RoAPAC: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 233 RoAPAC: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 234 RoAPAC: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 235 Latin America: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 236 Latin America: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 237 Latin America: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 238 Latin America: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 239 Latin America: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 240 Latin America: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 241 Brazil: Key Macroindicators
Table 242 Brazil: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 243 Brazil: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 244 Brazil: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 245 Brazil: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 246 Brazil: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 247 Brazil: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 248 Mexico: Key Macroindicators
Table 249 Mexico: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 250 Mexico: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 251 Mexico: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 252 Mexico: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 253 Mexico: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 254 Mexico: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 255 Rest of Latin America: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 256 Rest of Latin America: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 257 Rest of Latin America: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 258 Rest of Latin America: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 259 Rest of Latin America: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 260 Rest of Latin America: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 261 Middle East & Africa: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 262 Middle East & Africa: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 263 Middle East & Africa: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 264 Middle East & Africa: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 265 Middle East & Africa: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 266 Middle East & Africa: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 267 Middle East & Africa: Leukopaks Market, by Leukopak Type, 2024-2031 (Million Unit Bags)
Table 268 Kingdom of Saudi Arabia: Key Macroindicators
Table 269 Kingdom of Saudi Arabia (KSA): Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 270 Kingdom of Saudi Arabia (KSA): Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 271 Kingdom of Saudi Arabia (KSA): Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 272 Kingdom of Saudi Arabia (KSA): Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 273 Kingdom of Saudi Arabia (KSA): Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 274 Kingdom of Saudi Arabia (KSA): Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 275 United Arab Emirates (UAE): Key Macroindicators
Table 276 United Arab Emirates (UAE): Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 277 United Arab Emirates (UAE): Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 278 United Arab Emirates (UAE): Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 279 United Arab Emirates (UAE): Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 280 United Arab Emirates (UAE): Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 281 United Arab Emirates (UAE): Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 282 Other GCC Countries: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 283 Other GCC Countries: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 284 Other GCC Countries: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 285 Other GCC Countries: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 286 Other GCC Countries: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 287 Other GCC Countries: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 288 Rest of Middle East & Africa: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 289 Rest of Middle East & Africa: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 290 Rest of Middle East & Africa: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 291 Rest of Middle East & Africa: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 292 Rest of Middle East & Africa: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 293 Rest of Middle East & Africa: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 294 Overview of Strategies Deployed by Key Players in Leukapheresis Market, January 2023-March 2026
Table 295 Overview of Strategies Deployed by Key Players in Leukopaks Market, January 2023-March 2026
Table 296 Leukapheresis Market: Degree of Competition
Table 297 Leukopaks Market: Degree of Competition
Table 298 Leukopaks Market: Region Footprint
Table 299 Leukopaks Market: by Product Type Footprint
Table 300 Leukopaks Market: Detailed List of Key Startups/SMEs
Table 301 Leukopaks Market: Competitive Benchmarking of Key Startup/SME Players
Table 302 Leukapheresis Market: Product Launches & Approvals, January 2023-March 2026
Table 303 Leukapheresis Market: Deals, January 2023-March 2026
Table 304 Leukapheresis Market: Expansions, January 2023-March 2026
Table 305 Leukopaks Market: Product Launches & Approvals, January 2023-March 2026
Table 306 Leukopaks Market: Deals, January 2023-March 2026
Table 307 Leukopaks Market: Expansions, January 2023-March 2026
Table 308 Terumo Corporation: Company Overview
Table 309 Terumo Corporation: Products Offered
Table 310 Terumo Corporation: Product Launches & Approvals, January 2023-March 2026
Table 311 Terumo Corporation: Deals, January 2023-March 2026
Table 312 Terumo Corporation: Expansions, January 2023-March 2026
Table 313 Fresenius SE & Co. Kgaa: Company Overview
Table 314 Fresenius SE & Co. Kgaa: Products Offered
Table 315 Fresenius SE & Co. Kgaa: Product Launches & Approvals, January 2023-March 2026
Table 316 Fresenius SE & Co. Kgaa: Deals, January 2023-March 2026
Table 317 Fresenius SE & Co. Kgaa: Other Developments, January 2023-March 2026
Table 318 Haemonetics Corporation: Company Overview
Table 319 Haemonetics Corporation: Products Offered
Table 320 Haemonetics Corporation: Product Launches & Approvals, January 2023-March 2026
Table 321 Haemonetics Corporation: Deals, January 2023-March 2026
Table 322 Nikkiso Co. Ltd.: Company Overview
Table 323 Nikkiso Co. Ltd.: Products Offered
Table 324 Nikkiso Co. Ltd.: Other Developments, January 2023-March 2026
Table 325 Sumitomo Bakelite Co. Ltd.: Company Overview
Table 326 Sumitomo Bakelite Co. Ltd.: Products Offered
Table 327 Danaher Corporation: Company Overview
Table 328 Danaher Corporation: Products Offered
Table 329 Otsuka Holdings Co. Ltd.: Company Overview
Table 330 Otsuka Holdings Co. Ltd.: Products Offered
Table 331 Asahi Kasei Medical Co. Ltd.: Company Overview
Table 332 Asahi Kasei Medical Co. Ltd.: Products Offered
Table 333 Asahi Kasei Medical Co. Ltd.: Other Developments, January 2023-March 2026
Table 334 Macopharma SA: Company Overview
Table 335 Macopharma SA: Products Offered
Table 336 Medica Spa: Company Overview
Table 337 Medica Spa: Products Offered
Table 338 Polymed: Company Overview
Table 339 Puriblood Medical: Company Overview
Table 340 Guangzhou Daji Medical Science and Technology Co. Ltd.: Company Overview
Table 341 Safetran Biomedical Inc.: Company Overview
Table 342 Mitra Industries Private Limited: Company Overview
Table 343 Lonza: Company Overview
Table 344 Lonza: Products Offered
Table 345 Lonza: Deals, January 2023-March 2026
Table 346 Grifols: Company Overview
Table 347 Grifols: Products Offered
Table 348 Charles River Laboratories International, Inc.: Company Overview
Table 349 Charles River Laboratories: Products Offered
Table 350 Charles River Laboratories: Product Launches & Approvals, January 2023-March 2026
Table 351 Charles River Laboratories: Deals, January 2023-March 2026
Table 352 Charles River Laboratories: Expansions, January 2023-March 2026
Table 353 Cellex Cell Professionals: Company Overview
Table 354 Cellex Cell Professionals: Products Offered
Table 355 Cellex Cell Professionals: Deals, January 2023-March 2026
Table 356 Cellex Cells Professionals: Expansions, January 2023-March 2026
Table 357 Stemcell Technologies: Company Overview
Table 358 Stemcell Technologies: Products Offered
Table 359 Bioivt: Company Overview
Table 360 Bioivt: Products Offered
Table 361 Bioivt: Product Launches & Approvals, January 2023-March 2026
Table 362 Bioivt: Deals, January 2023-March 2026
Table 363 Bioivt: Expansions, January 2023-March 2026
Table 364 Discovery Life Sciences: Company Overview
Table 365 Discovery Life Sciences: Products Offered
Table 366 Discovery Life Sciences: Product Launches & Approvals, January 2023-March 2026
Table 367 Discovery Life Sciences: Deals, January 2023-March 2026
Table 368 Discovery Life Sciences: Expansions, January 2023-March 2026
Table 369 Miltenyi Biotec: Company Overview
Table 370 Miltenyi Biotec: Products Offered
Table 371 Stemvivo Inc.: Company Overview
Table 372 Stemvivo Inc.: Products Offered
Table 373 Cgt Global: Company Overview
Table 374 Cgt Global: Products Offered
Table 375 Cgt Global: Product Launches & Approvals, January 2023-March 2026
Table 376 Sanguine Biosciences: Company Overview
Table 377 Sanguine Biosciences: Products Offered
Table 378 Sanguine Biosciences: Product Launches & Approvals, January 2023-March 2026
Table 379 Biomex GmbH: Company Overview
Table 380 Accegen: Company Overview
Table 381 Excellos: Company Overview
Table 382 First Choice Bio Inc.: Company Overview
Table 383 Organa Bio: Company Overview
Table 384 Human Cells Bio: Company Overview
Table 385 Impact Analysis of Supply- and Demand-Side Factors on Leukapheresis Market
Table 386 Risk Assessment: Leukapheresis Market
Table 2 Exchange Rates Utilized for Conversion to USD
Table 3 Cost of Leukopaks, by Type
Table 4 Donor Selection Criteria
Table 5 Frequency of Blood Donation From Healthy Donors
Table 6 Leukapheresis Market: Porter’S Five Forces Analysis
Table 7 GDP Change, by Key Country, 2021-2030 (USD Billion)
Table 8 List of Key Leukapheresis Devices + Disposables Manufacturers
Table 9 List of Key Leukopaks Manufacturers
Table 10 List of Key End Users
Table 11 List of Key Regulatory Bodies
Table 12 Average Selling Price of Non-Mobilized Leukopaks, 2025 (USD)
Table 13 Average Selling Price of Mobilized Leukopaks, 2025 (USD)
Table 14 Average Selling Price of Diseased Leukopaks, 2025 (USD)
Table 15 Average Selling Price of Isolated Pbmcs, 2025 (USD)
Table 16 Import Data for Hs Code 901890-Compliant Products, by Country, 2021-2025 (USD Thousand)
Table 17 Export Data for Hs Code 901890-Compliant Products, by Country, 2021-2025 (USD Thousand)
Table 18 Leukapheresis Market: Major Conferences & Events in 2026-2027
Table 19 Case Study 1: Rapid Cytoreduction in Pediatric Acute Leukemia Using Leukapheresis
Table 20 Case Study 2: Global Cell Therapy Trial Enabled by Leukapheresis Integration
Table 21 Case Study 3: Therapeutic Leukapheresis in Severe Pneumonia With Hyperleukocytosis
Table 22 US-Adjusted Reciprocal Tariff Rates, 2024
Table 23 Key Product-Related Tariff Effective
Table 24 North America: Impact of US Tariffs
Table 25 Asia-Pacific: Impact of US Tariffs
Table 26 Europe: Impact of US Tariffs
Table 27 Latin America: Impact of US Tariffs
Table 28 Leukapheresis Market: Key Patents, 2023-2025
Table 29 North America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 30 Europe: Regulatory Bodies, Government Agencies, and Other Organizations
Table 31 Asia-Pacific: Regulatory Bodies, Government Agencies, and Other Organizations
Table 32 Latin America: Regulatory Bodies, Government Agencies, and Other Organizations
Table 33 Middle East & Africa: Regulatory Bodies, Government Agencies, and Other Organizations
Table 34 Influence of Stakeholders on Buying Process of Leukopaks
Table 35 Key Buying Criteria for Leukopaks, by Type
Table 36 Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 37 Disposables: Leukapheresis Market, by Product Type 2024-2031 (USD Million)
Table 38 Leukapheresis Disposable Products Market, by Country, 2024-2031 (USD Million)
Table 39 Tubing Sets & Collection Bags Market, by Type, 2024-2031 (USD Million)
Table 40 Commercially Available Filters & Membrane Consumables
Table 41 Filters & Membrane Consumables Market, by Type, 2024-2031 (USD Million)
Table 42 Commercially Available Collection Kits & Accessories
Table 43 Collection Kits & Accessories Market, by Type,2024-2031 (USD Million)
Table 44 Leukapheresis Devices Market, by Type, 2024-2031 (USD Million)
Table 45 Centrifugal Devices Available
Table 46 Centrifugal Devices Market, by Country, 2024-2031 (USD Million)
Table 47 Centrifugal Devices Volume Market, 2024-2031 (Units Sold)
Table 48 Membrane Separators Available
Table 49 Membrane Separators Market, by Country, 2024-2031 (USD Million)
Table 50 Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 51 Companies Developing Fda-Approved Car-T Cell Therapies
Table 52 Leukapheresis Market in Research Applications, by Country, 2024-2031 (USD Million)
Table 53 Leukapheresis Market in Therapeutic Applications, by Country, 2024-2031 (USD Million)
Table 54 Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 55 Leukapheresis Market for Blood Component Providers & Blood Centers, by Country, 2024-2031 (USD Million)
Table 56 Leukapheresis Market for Hospitals & Transfusion Centers, by Country, 2024-2031 (USD Million)
Table 57 Leukapheresis Market for Academic & Research Institutes, by Country, 2024-2031 (USD Million)
Table 58 Car-T Cell Therapy Under Clinical Trials
Table 59 Leukapheresis Products Market for Pharmaceutical & Biotechnology Companies, by Country, 2024-2031 (USD Million)
Table 60 Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 61 Leukopaks Market, by Country, 2024-2031 (USD Million)
Table 62 Mobilized Leukopaks Market, by Country, 2024-2031 (USD Million)
Table 63 Mobilized Leukopaks Market Volume, by Region, 2024-2031 (No. of Bags)
Table 64 Number of Cells in Non-Mobilized Leukopaks
Table 65 Comparative Analysis of Mobilized and Non-Mobilized Leukopaks
Table 66 Composition of Mobilized and Non-Mobilized Leukopaks
Table 67 Non-Mobilized Leukopaks Market, by Country, 2024-2031 (USD Million)
Table 68 Non-Mobilized Leukopaks Market Volume, by Region, 2024-2031 (No. of Bags)
Table 69 Diseased Cell Leukopaks and Their Role in Cell Therapy
Table 70 Diseased Leukopaks Market, by Country, 2024-2031 (USD Million)
Table 71 Diseased Leukopaks Market Volume, by Region, 2024-2031 (No. of Bags)
Table 72 Immune Cell Types and Targeted Diseases
Table 73 Isolated Pbmcs Market, by Country, 2024-2031 (USD Million)
Table 74 Isolated Pbmcs Market Volume, by Region, 2024-2031 (No. of Bags)
Table 75 Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 76 Leukopaks Market for Acute Lymphocytic Leukemia, by Country, 2024-2031 (USD Million)
Table 77 Leukopaks Market for Multiple Myeloma, by Country, 2024-2031 (USD Million)
Table 78 Leukopaks Market for Non-Hodgkin’S Lymphoma, by Country, 2024-2031 (USD Million)
Table 79 Leukopaks Market for Chronic Lymphocytic Leukemia, by Country, 2024-2031 (USD Million)
Table 80 Leukopaks Market for Pancreatic Cancer, by Country, 2024-2031 (USD Million)
Table 81 Leukopaks Market for Hepatocellular Carcinoma, by Country, 2024-2031 (USD Million)
Table 82 Leukopaks Market for Other Indications, by Country, 2024-2031 (USD Million)
Table 83 Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 84 Leukopaks Market for Academic & Research Institutes, by Country, 2024-2031 (USD Million)
Table 85 Leukopaks Market for Pharmaceutical & Biotechnology Companies, by Country, 2024-2031 (USD Million)
Table 86 Leukopaks Market for Contract Research Organizations, by Country, 2024-2031 (USD Million)
Table 87 Leukapheresis Products Market, by Region, 2024-2031 (USD Million)
Table 88 Leukopaks Market, by Region, 2024-2031 (USD Million)
Table 89 Major Leukapheresis Market Players in North America
Table 90 North America: Leukapheresis Market, by Country, 2024-2031 (USD Million)
Table 91 North America: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 92 North America: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 93 North America: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 94 North America: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 95 North America: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 96 North America: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 97 US: Key Macroindicators
Table 98 US: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 99 US: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 100 US: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 101 US: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 102 US: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 103 US: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 104 Canada: Key Macroindicators
Table 105 Canada: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 106 Canada: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 107 Canada: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 108 Canada: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 109 Canada: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 110 Canada: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 111 Europe: Leukopaks Market, by Leukopak Type, 2024-2031 (Million Unit Bags)
Table 112 Europe: Leukapheresis Market, by Country, 2024-2031 (USD Million)
Table 113 Europe: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 114 Europe: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 115 Europe: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 116 Europe: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 117 Europe: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 118 Europe: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 119 Germany: Key Macroindicators
Table 120 Germany: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 121 Germany: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 122 Germany: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 123 Germany: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 124 Germany: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 125 Germany: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 126 UK: Key Macroindicators
Table 127 UK: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 128 UK: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 129 UK: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 130 UK: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 131 UK: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 132 UK: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 133 France: Key Macroindicators
Table 134 Spain: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 135 Spain: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 136 Spain: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 137 Spain: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 138 Italy: Key Macroindicators
Table 139 Italy: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 140 Italy: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 141 Italy: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 142 Italy: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 143 Italy: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 144 Italy: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 145 Spain: Key Macroindicators
Table 146 Netherlands: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 147 Netherlands: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 148 Netherlands: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 149 Netherlands: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 150 Netherlands: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 151 Netherlands: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 152 Poland: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 153 Poland: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 154 Poland: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 155 Poland: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 156 Poland: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 157 Poland: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 158 Switzerland: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 159 Switzerland: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 160 Switzerland: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 161 Switzerland: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 162 Switzerland: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 163 Switzerland: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 164 Rest of Europe: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 165 Rest of Europe: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 166 Rest of Europe: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 167 Rest of Europe: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 168 Rest of Europe: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 169 Rest of Europe: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 170 Asia-Pacific: Leukapheresis Market, by Country, 2024-2031 (USD Million)
Table 171 Asia-Pacific: Leukopak Products Market, by Country, 2024-2031 (USD Million)
Table 172 Asia-Pacific: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 173 Asia-Pacific: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 174 Asia-Pacific: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 175 Asia-Pacific: Leukopaks Market, by Country, 2024-2031 (USD Million)
Table 176 Asia-Pacific: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 177 Asia-Pacific: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 178 Asia-Pacific: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 179 Asia-Pacific: Leukopaks Market, by Leukopak Type, 2024-2031 (Million Unit Bags)
Table 180 China: Key Macroindicators
Table 181 China: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 182 China: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 183 China: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 184 China: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 185 China: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 186 China: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 187 Japan: Key Macroindicators
Table 188 Japan: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 189 Japan: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 190 Japan: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 191 Japan: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 192 Japan: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 193 Japan: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 194 India: Key Macroindicators
Table 195 India: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 196 India: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 197 India: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 198 India: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 199 India: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 200 India: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 201 Australia: Key Macroindicators
Table 202 Australia: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 203 Australia: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 204 Australia: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 205 Australia: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 206 Australia: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 207 Australia: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 208 South Korea: Key Macroindicators
Table 209 South Korea: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 210 South Korea: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 211 South Korea: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 212 South Korea: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 213 South Korea: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 214 South Korea: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 215 New Zealand: Key Macroindicators
Table 216 New Zealand: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 217 New Zealand: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 218 New Zealand: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 219 New Zealand: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 220 New Zealand: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 221 New Zealand: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 222 Thailand: Key Macroindicators
Table 223 Thailand: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 224 Thailand: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 225 Thailand: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 226 Thailand: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 227 Thailand: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 228 Thailand: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 229 RoAPAC: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 230 RoAPAC: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 231 RoAPAC: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 232 RoAPAC: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 233 RoAPAC: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 234 RoAPAC: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 235 Latin America: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 236 Latin America: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 237 Latin America: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 238 Latin America: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 239 Latin America: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 240 Latin America: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 241 Brazil: Key Macroindicators
Table 242 Brazil: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 243 Brazil: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 244 Brazil: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 245 Brazil: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 246 Brazil: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 247 Brazil: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 248 Mexico: Key Macroindicators
Table 249 Mexico: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 250 Mexico: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 251 Mexico: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 252 Mexico: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 253 Mexico: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 254 Mexico: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 255 Rest of Latin America: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 256 Rest of Latin America: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 257 Rest of Latin America: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 258 Rest of Latin America: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 259 Rest of Latin America: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 260 Rest of Latin America: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 261 Middle East & Africa: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 262 Middle East & Africa: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 263 Middle East & Africa: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 264 Middle East & Africa: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 265 Middle East & Africa: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 266 Middle East & Africa: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 267 Middle East & Africa: Leukopaks Market, by Leukopak Type, 2024-2031 (Million Unit Bags)
Table 268 Kingdom of Saudi Arabia: Key Macroindicators
Table 269 Kingdom of Saudi Arabia (KSA): Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 270 Kingdom of Saudi Arabia (KSA): Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 271 Kingdom of Saudi Arabia (KSA): Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 272 Kingdom of Saudi Arabia (KSA): Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 273 Kingdom of Saudi Arabia (KSA): Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 274 Kingdom of Saudi Arabia (KSA): Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 275 United Arab Emirates (UAE): Key Macroindicators
Table 276 United Arab Emirates (UAE): Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 277 United Arab Emirates (UAE): Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 278 United Arab Emirates (UAE): Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 279 United Arab Emirates (UAE): Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 280 United Arab Emirates (UAE): Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 281 United Arab Emirates (UAE): Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 282 Other GCC Countries: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 283 Other GCC Countries: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 284 Other GCC Countries: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 285 Other GCC Countries: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 286 Other GCC Countries: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 287 Other GCC Countries: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 288 Rest of Middle East & Africa: Leukapheresis Market, by Product Type, 2024-2031 (USD Million)
Table 289 Rest of Middle East & Africa: Leukapheresis Market, by Application, 2024-2031 (USD Million)
Table 290 Rest of Middle East & Africa: Leukapheresis Market, by End User, 2024-2031 (USD Million)
Table 291 Rest of Middle East & Africa: Leukopaks Market, by Type, 2024-2031 (USD Million)
Table 292 Rest of Middle East & Africa: Leukopaks Market, by Indication, 2024-2031 (USD Million)
Table 293 Rest of Middle East & Africa: Leukopaks Market, by End User, 2024-2031 (USD Million)
Table 294 Overview of Strategies Deployed by Key Players in Leukapheresis Market, January 2023-March 2026
Table 295 Overview of Strategies Deployed by Key Players in Leukopaks Market, January 2023-March 2026
Table 296 Leukapheresis Market: Degree of Competition
Table 297 Leukopaks Market: Degree of Competition
Table 298 Leukopaks Market: Region Footprint
Table 299 Leukopaks Market: by Product Type Footprint
Table 300 Leukopaks Market: Detailed List of Key Startups/SMEs
Table 301 Leukopaks Market: Competitive Benchmarking of Key Startup/SME Players
Table 302 Leukapheresis Market: Product Launches & Approvals, January 2023-March 2026
Table 303 Leukapheresis Market: Deals, January 2023-March 2026
Table 304 Leukapheresis Market: Expansions, January 2023-March 2026
Table 305 Leukopaks Market: Product Launches & Approvals, January 2023-March 2026
Table 306 Leukopaks Market: Deals, January 2023-March 2026
Table 307 Leukopaks Market: Expansions, January 2023-March 2026
Table 308 Terumo Corporation: Company Overview
Table 309 Terumo Corporation: Products Offered
Table 310 Terumo Corporation: Product Launches & Approvals, January 2023-March 2026
Table 311 Terumo Corporation: Deals, January 2023-March 2026
Table 312 Terumo Corporation: Expansions, January 2023-March 2026
Table 313 Fresenius SE & Co. Kgaa: Company Overview
Table 314 Fresenius SE & Co. Kgaa: Products Offered
Table 315 Fresenius SE & Co. Kgaa: Product Launches & Approvals, January 2023-March 2026
Table 316 Fresenius SE & Co. Kgaa: Deals, January 2023-March 2026
Table 317 Fresenius SE & Co. Kgaa: Other Developments, January 2023-March 2026
Table 318 Haemonetics Corporation: Company Overview
Table 319 Haemonetics Corporation: Products Offered
Table 320 Haemonetics Corporation: Product Launches & Approvals, January 2023-March 2026
Table 321 Haemonetics Corporation: Deals, January 2023-March 2026
Table 322 Nikkiso Co. Ltd.: Company Overview
Table 323 Nikkiso Co. Ltd.: Products Offered
Table 324 Nikkiso Co. Ltd.: Other Developments, January 2023-March 2026
Table 325 Sumitomo Bakelite Co. Ltd.: Company Overview
Table 326 Sumitomo Bakelite Co. Ltd.: Products Offered
Table 327 Danaher Corporation: Company Overview
Table 328 Danaher Corporation: Products Offered
Table 329 Otsuka Holdings Co. Ltd.: Company Overview
Table 330 Otsuka Holdings Co. Ltd.: Products Offered
Table 331 Asahi Kasei Medical Co. Ltd.: Company Overview
Table 332 Asahi Kasei Medical Co. Ltd.: Products Offered
Table 333 Asahi Kasei Medical Co. Ltd.: Other Developments, January 2023-March 2026
Table 334 Macopharma SA: Company Overview
Table 335 Macopharma SA: Products Offered
Table 336 Medica Spa: Company Overview
Table 337 Medica Spa: Products Offered
Table 338 Polymed: Company Overview
Table 339 Puriblood Medical: Company Overview
Table 340 Guangzhou Daji Medical Science and Technology Co. Ltd.: Company Overview
Table 341 Safetran Biomedical Inc.: Company Overview
Table 342 Mitra Industries Private Limited: Company Overview
Table 343 Lonza: Company Overview
Table 344 Lonza: Products Offered
Table 345 Lonza: Deals, January 2023-March 2026
Table 346 Grifols: Company Overview
Table 347 Grifols: Products Offered
Table 348 Charles River Laboratories International, Inc.: Company Overview
Table 349 Charles River Laboratories: Products Offered
Table 350 Charles River Laboratories: Product Launches & Approvals, January 2023-March 2026
Table 351 Charles River Laboratories: Deals, January 2023-March 2026
Table 352 Charles River Laboratories: Expansions, January 2023-March 2026
Table 353 Cellex Cell Professionals: Company Overview
Table 354 Cellex Cell Professionals: Products Offered
Table 355 Cellex Cell Professionals: Deals, January 2023-March 2026
Table 356 Cellex Cells Professionals: Expansions, January 2023-March 2026
Table 357 Stemcell Technologies: Company Overview
Table 358 Stemcell Technologies: Products Offered
Table 359 Bioivt: Company Overview
Table 360 Bioivt: Products Offered
Table 361 Bioivt: Product Launches & Approvals, January 2023-March 2026
Table 362 Bioivt: Deals, January 2023-March 2026
Table 363 Bioivt: Expansions, January 2023-March 2026
Table 364 Discovery Life Sciences: Company Overview
Table 365 Discovery Life Sciences: Products Offered
Table 366 Discovery Life Sciences: Product Launches & Approvals, January 2023-March 2026
Table 367 Discovery Life Sciences: Deals, January 2023-March 2026
Table 368 Discovery Life Sciences: Expansions, January 2023-March 2026
Table 369 Miltenyi Biotec: Company Overview
Table 370 Miltenyi Biotec: Products Offered
Table 371 Stemvivo Inc.: Company Overview
Table 372 Stemvivo Inc.: Products Offered
Table 373 Cgt Global: Company Overview
Table 374 Cgt Global: Products Offered
Table 375 Cgt Global: Product Launches & Approvals, January 2023-March 2026
Table 376 Sanguine Biosciences: Company Overview
Table 377 Sanguine Biosciences: Products Offered
Table 378 Sanguine Biosciences: Product Launches & Approvals, January 2023-March 2026
Table 379 Biomex GmbH: Company Overview
Table 380 Accegen: Company Overview
Table 381 Excellos: Company Overview
Table 382 First Choice Bio Inc.: Company Overview
Table 383 Organa Bio: Company Overview
Table 384 Human Cells Bio: Company Overview
Table 385 Impact Analysis of Supply- and Demand-Side Factors on Leukapheresis Market
Table 386 Risk Assessment: Leukapheresis Market
List of Figures
Figure 1 Leukapheresis Market: Segmentation & Regional Scope
Figure 2 Leukapheresis Market: Years Considered
Figure 3 Market Scenario
Figure 4 Leukapheresis Market, 2026-2031
Figure 5 Major Strategies Adopted by Key Players in Leukopaks Market, 2024-2026
Figure 6 Major Strategies Adopted by Key Players in Leukapheresis Market, 2024-2026
Figure 7 Disruptions Influencing Growth of Leukapheresis Market
Figure 8 High-Growth Segments in Leukopaks Market, 2026-2031
Figure 9 High-Growth Segments in Leukapheresis Market, 2026-2031
Figure 10 Asia-Pacific to Register Highest Cagr in Leukapheresis Market, in Terms of Value, During Forecast Period
Figure 11 Asia-Pacific to Register Highest Cagr in Leukopaks Market, in Terms of Value, During Forecast Period
Figure 12 Growing Incidence of Cancer to Drive Market
Figure 13 Blood Component Providers and Blood Centers Segment and Japan Accounted for Largest Market Shares in 2025
Figure 14 China to Witness Highest Cagr During Forecast Period
Figure 15 Growing Prevalence of Leukemia and Adoption of Car T-Cell Therapy to Drive Market
Figure 16 Mobilized Leukopaks Segment and China Accounted for Largest Market Shares in 2025
Figure 17 China to Witness Highest Cagr During Forecast Period
Figure 18 Leukapheresis Market: Drivers, Restraints, Opportunities, and Challenges
Figure 19 Estimated Number of New Leukemia Cases, by Region (2020 Vs. 2040)
Figure 20 Estimated Number of Leukemia Deaths, by Region (2020 Vs. 2040)
Figure 21 Leukapheresis Market: Porter's Five Forces Analysis
Figure 22 Leukapheresis Market: Supply Chain Analysis
Figure 23 Leukapheresis Market: Value Chain Analysis
Figure 24 Leukopaks Market: Value Chain Analysis
Figure 25 Leukapheresis Market Ecosystem
Figure 26 Trends/Disruptions Impacting Customer Business in Leukapheresis Market
Figure 27 Trends/Disruptions Impacting Customers’ Businesses in Leukopaks Market
Figure 28 Investment & Funding Scenario for Leukapheresis Market Players
Figure 29 Top Applicants/Owners (Companies/Institutions) for Leukapheresis Patents (January 2015-March 2026)
Figure 30 Leukapheresis Market: AI Use Cases
Figure 31 Influence of Stakeholders on Buying Process of Leukopaks
Figure 32 Key Buying Criteria for Leukopaks, by Type
Figure 33 North America: Leukapheresis Market Snapshot
Figure 34 North America Volume Analysis: Leukopaks Type, 2024-2031 (No. of Bags)
Figure 35 Europe Volume Analysis: Leukopaks Type, 2024-2031 (No. of Bags)
Figure 36 Asia-Pacific: Leukapheresis Market Snapshot
Figure 37 Asia-Pacific Volume Analysis: Leukopaks Type, 2024-2031 (No. of Bags)
Figure 38 Latin America Volume Analysis: Leukopaks Type, 2024-2031 (No. of Bags)
Figure 39 Middle East & Africa Volume Analysis: Leukopaks Type, 2024-2031 (No. of Bags)
Figure 40 Revenue Analysis of Key Players in Leukapheresis Market, 2023-2025
Figure 41 Revenue Analysis of Key Players in Leukopaks Market, 2023-2025
Figure 42 Market Share Analysis of Key Players in Leukapheresis Market, 2025
Figure 43 Market Share Analysis of Key Players in Leukopaks Market, 2025
Figure 44 Leukopaks Market: Company Evaluation Matrix (Key Players), 2025
Figure 45 Leukopaks Market: Company Footprint
Figure 46 Leukopaks Market: Company Evaluation Matrix (Startups/SMEs), 2025
Figure 47 Ev/EBITDA of Key Vendors for Leukapheresis
Figure 48 Year-to-Date (YTD) Price, Total Return and 5-Year Stock Beta of Key Vendors for Leukapheresis
Figure 49 Ev/EBITDA of Key Vendors for Leukopaks
Figure 50 Year-to-Date (YTD) Price, Total Return and 5-Year Stock Beta of Key Vendors for Leukopaks
Figure 51 Leukopaks Market: Brand/Product Comparative Analysis
Figure 52 Leukapheresis Market: Brand/Product Comparative Analysis
Figure 53 Terumo Corporation: Company Snapshot (2025)
Figure 54 Fresenius SE & Co. Kgaa: Company Snapshot (2025)
Figure 55 Haemonetics Corporation: Company Snapshot (2025)
Figure 56 Nikkiso Co. Ltd.: Company Snapshot (2025)
Figure 57 Sumitomo Bakelite Co. Ltd.: Company Snapshot (2025)
Figure 58 Danaher Corporation: Company Snapshot (2025)
Figure 59 Otsuka Holdings Co. Ltd.: Company Snapshot (2025)
Figure 60 Lonza: Company Snapshot (2025)
Figure 61 Grifols: Company Snapshot (2025)
Figure 62 Charles River Laboratories International, Inc.: Company Snapshot (2025)
Figure 63 Leukapheresis Market: Research Design
Figure 64 Breakdown of Primary Interviews: Supply- and Demand-Side Participants (Leukapheresis Products and Leukopaks Market)
Figure 65 Breakdown of Primary Interviews (Supply Side): by Company Type, Designation, and Region (Leukapheresis Market)
Figure 66 Breakdown of Primary Interviews (Demand Side): by End User and Region (Leukapheresis Market)
Figure 67 Breakdown of Primary Interviews (Supply Side): by Company Type, Designation, and Region (Leukopaks Market)
Figure 68 Breakdown of Primary Interviews (Demand Side): by End User and Region (Leukopaks Market)
Figure 69 Supply-Side Market Size Estimation: Revenue Share Analysis
Figure 70 Revenue Share Analysis Illustration: Terumo Corporation (2025)
Figure 71 Demand-Side Approach: Leukapheresis Market (2025)
Figure 72 Leukapheresis Market: Cagr Projections (2026-2031)
Figure 73 Top-Down Approach
Figure 74 Data Triangulation Methodology
Figure 2 Leukapheresis Market: Years Considered
Figure 3 Market Scenario
Figure 4 Leukapheresis Market, 2026-2031
Figure 5 Major Strategies Adopted by Key Players in Leukopaks Market, 2024-2026
Figure 6 Major Strategies Adopted by Key Players in Leukapheresis Market, 2024-2026
Figure 7 Disruptions Influencing Growth of Leukapheresis Market
Figure 8 High-Growth Segments in Leukopaks Market, 2026-2031
Figure 9 High-Growth Segments in Leukapheresis Market, 2026-2031
Figure 10 Asia-Pacific to Register Highest Cagr in Leukapheresis Market, in Terms of Value, During Forecast Period
Figure 11 Asia-Pacific to Register Highest Cagr in Leukopaks Market, in Terms of Value, During Forecast Period
Figure 12 Growing Incidence of Cancer to Drive Market
Figure 13 Blood Component Providers and Blood Centers Segment and Japan Accounted for Largest Market Shares in 2025
Figure 14 China to Witness Highest Cagr During Forecast Period
Figure 15 Growing Prevalence of Leukemia and Adoption of Car T-Cell Therapy to Drive Market
Figure 16 Mobilized Leukopaks Segment and China Accounted for Largest Market Shares in 2025
Figure 17 China to Witness Highest Cagr During Forecast Period
Figure 18 Leukapheresis Market: Drivers, Restraints, Opportunities, and Challenges
Figure 19 Estimated Number of New Leukemia Cases, by Region (2020 Vs. 2040)
Figure 20 Estimated Number of Leukemia Deaths, by Region (2020 Vs. 2040)
Figure 21 Leukapheresis Market: Porter's Five Forces Analysis
Figure 22 Leukapheresis Market: Supply Chain Analysis
Figure 23 Leukapheresis Market: Value Chain Analysis
Figure 24 Leukopaks Market: Value Chain Analysis
Figure 25 Leukapheresis Market Ecosystem
Figure 26 Trends/Disruptions Impacting Customer Business in Leukapheresis Market
Figure 27 Trends/Disruptions Impacting Customers’ Businesses in Leukopaks Market
Figure 28 Investment & Funding Scenario for Leukapheresis Market Players
Figure 29 Top Applicants/Owners (Companies/Institutions) for Leukapheresis Patents (January 2015-March 2026)
Figure 30 Leukapheresis Market: AI Use Cases
Figure 31 Influence of Stakeholders on Buying Process of Leukopaks
Figure 32 Key Buying Criteria for Leukopaks, by Type
Figure 33 North America: Leukapheresis Market Snapshot
Figure 34 North America Volume Analysis: Leukopaks Type, 2024-2031 (No. of Bags)
Figure 35 Europe Volume Analysis: Leukopaks Type, 2024-2031 (No. of Bags)
Figure 36 Asia-Pacific: Leukapheresis Market Snapshot
Figure 37 Asia-Pacific Volume Analysis: Leukopaks Type, 2024-2031 (No. of Bags)
Figure 38 Latin America Volume Analysis: Leukopaks Type, 2024-2031 (No. of Bags)
Figure 39 Middle East & Africa Volume Analysis: Leukopaks Type, 2024-2031 (No. of Bags)
Figure 40 Revenue Analysis of Key Players in Leukapheresis Market, 2023-2025
Figure 41 Revenue Analysis of Key Players in Leukopaks Market, 2023-2025
Figure 42 Market Share Analysis of Key Players in Leukapheresis Market, 2025
Figure 43 Market Share Analysis of Key Players in Leukopaks Market, 2025
Figure 44 Leukopaks Market: Company Evaluation Matrix (Key Players), 2025
Figure 45 Leukopaks Market: Company Footprint
Figure 46 Leukopaks Market: Company Evaluation Matrix (Startups/SMEs), 2025
Figure 47 Ev/EBITDA of Key Vendors for Leukapheresis
Figure 48 Year-to-Date (YTD) Price, Total Return and 5-Year Stock Beta of Key Vendors for Leukapheresis
Figure 49 Ev/EBITDA of Key Vendors for Leukopaks
Figure 50 Year-to-Date (YTD) Price, Total Return and 5-Year Stock Beta of Key Vendors for Leukopaks
Figure 51 Leukopaks Market: Brand/Product Comparative Analysis
Figure 52 Leukapheresis Market: Brand/Product Comparative Analysis
Figure 53 Terumo Corporation: Company Snapshot (2025)
Figure 54 Fresenius SE & Co. Kgaa: Company Snapshot (2025)
Figure 55 Haemonetics Corporation: Company Snapshot (2025)
Figure 56 Nikkiso Co. Ltd.: Company Snapshot (2025)
Figure 57 Sumitomo Bakelite Co. Ltd.: Company Snapshot (2025)
Figure 58 Danaher Corporation: Company Snapshot (2025)
Figure 59 Otsuka Holdings Co. Ltd.: Company Snapshot (2025)
Figure 60 Lonza: Company Snapshot (2025)
Figure 61 Grifols: Company Snapshot (2025)
Figure 62 Charles River Laboratories International, Inc.: Company Snapshot (2025)
Figure 63 Leukapheresis Market: Research Design
Figure 64 Breakdown of Primary Interviews: Supply- and Demand-Side Participants (Leukapheresis Products and Leukopaks Market)
Figure 65 Breakdown of Primary Interviews (Supply Side): by Company Type, Designation, and Region (Leukapheresis Market)
Figure 66 Breakdown of Primary Interviews (Demand Side): by End User and Region (Leukapheresis Market)
Figure 67 Breakdown of Primary Interviews (Supply Side): by Company Type, Designation, and Region (Leukopaks Market)
Figure 68 Breakdown of Primary Interviews (Demand Side): by End User and Region (Leukopaks Market)
Figure 69 Supply-Side Market Size Estimation: Revenue Share Analysis
Figure 70 Revenue Share Analysis Illustration: Terumo Corporation (2025)
Figure 71 Demand-Side Approach: Leukapheresis Market (2025)
Figure 72 Leukapheresis Market: Cagr Projections (2026-2031)
Figure 73 Top-Down Approach
Figure 74 Data Triangulation Methodology
Companies Mentioned
- Darling Ingredients
- Nippi, Inc.
- Weishardt
- Nitta Gelatin Inc.
- Vinh Hoan Corporation
- Hainan Huayan Collagen Technology Co. Ltd.
- Gelita
- Seagarden as
- Tessenderlo Group
- Italgel S.P.A.
- Ashland
- Titan Biotech
- Amicogen Inc.
- Croda International PLC
- Jellice
- Lapi Gelatine S.P.A.
- Certified Nutraceuticals Inc.
- Athos Collagen Pvt. Ltd.
- Collagen Life Sciences
- Etchem
- Jellagen
- Beijing Semnl Biotechnology Co. Ltd.
- Copalis Sea Solutions
- Nizona Marine Products Private Limited
- Hangzhou Nutrition Biotechnology Co. Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 411 |
| Published | February 2026 |
| Forecast Period | 2026 - 2031 |
| Estimated Market Value ( USD | $ 90.6 Million |
| Forecasted Market Value ( USD | $ 138.7 Million |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
